0000950170-22-003369 | 10-K | XBRL Viewer

Print Document View Excel Document

Statements of Convertible Preferred Stock and Stockholders' Equity (Deficit) - USD ($) $ in Thousands	Total	Convertible Preferred Stock	Common Stock	Additional Paid-in Capital	Accumulated Other Comprehensive Income (Loss)	Accumulated Deficit
Beginning Balance at Dec. 31, 2019	$ (3,642)		$ 1			$ (3,643)
Beginning Balance, Shares at Dec. 31, 2019			15,640,133
Issuance of Series A and Series B convertible preferred stock, net of issuance costs		$ 44,731
Issuance of Series A and Series B convertible preferred stock, net of issuance costs, Shares		21,710,814
Conversion of convertible debt and interest to Series A convertible preferred stock		$ 500
Conversion of convertible debt and interest to Series A convertible preferred stock, Shares		301,685
Settlement of bifurcated conversion liability		$ 125
Exercises of stock options and vesting of restricted stock	1			$ 1
Exercises of stock options and vesting of restricted stock, Shares			317,688
Stock-based compensation	450			450
Unrealized gain (loss) on investments	156				$ 156
Net loss	(8,280)					(8,280)
Ending Balance at Dec. 31, 2020	$ (11,315)		$ 1	451	156	(11,923)
Ending Balance, Shares at Dec. 31, 2020	22,012,499	22,012,499
Ending Balance at Dec. 31, 2020	$ 45,356	$ 45,356
Ending Balance, Shares at Dec. 31, 2020			15,957,821
Issuance of Series A and Series B convertible preferred stock, net of issuance costs		$ 124,712
Issuance of Series A and Series B convertible preferred stock, net of issuance costs, Shares		19,083,979
Preferred stock converted into shares of common stock	170,068		$ 4	170,064
Preferred stock converted into shares of common stock, Shares		(41,096,478)
Preferred stock converted into shares of common stock		$ (170,068)
Preferred stock converted into shares of common stock, Shares			25,212,548
Initial public offering of common shares, net of $21,728 of issuance costs	254,271		$ 1	254,270
Initial public offering of common shares, net of $21,728 of issuance costs, Shares			13,800,000
Exercises of stock options and vesting of restricted stock	156			156
Exercises of stock options and vesting of restricted stock, Shares			460,101
Issuance of common stock under employee stock purchase plan	194			194
Issuance of common stock under employee stock purchase plan, Shares			11,456
Stock-based compensation	4,689			4,689
Unrealized gain (loss) on investments	(400)				(400)
Net loss	(35,533)					(35,533)
Ending Balance at Dec. 31, 2021	$ 382,130		$ 6	$ 429,824	$ (244)	$ (47,456)
Ending Balance, Shares at Dec. 31, 2021	0
Ending Balance, Shares at Dec. 31, 2021			55,441,926

Statements of Comprehensive Loss - USD ($) $ in Thousands	12 Months Ended
Statements of Comprehensive Loss - USD ($) $ in Thousands	Dec. 31, 2021	Dec. 31, 2020
Statement Of Income And Comprehensive Income [Abstract]
Net loss	$ (35,533)	$ (8,280)
Other comprehensive gain (loss):
Unrealized gain (loss) on available-for-sale securities	(400)	156
Comprehensive loss	$ (35,933)	$ (8,124)

- Definition

The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-04(22))
-URI http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-Subparagraph (f)
-URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=124431687&loc=d3e22595-107794

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-04(18))
-URI http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 40
-Section 65
-Paragraph 1
-Subparagraph (f)
-URI http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 50
-Paragraph 6
-URI http://asc.fasb.org/extlink&oid=124431353&loc=SL124452729-227067

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(5))
-URI http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756

Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03(20))
-URI http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227

Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-URI http://asc.fasb.org/extlink&oid=123570139&loc=d3e3602-108585

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (b)(2)
-URI http://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(iv))
-URI http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(iii)(A))
-URI http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(i))
-URI http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756

Reference 14: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(i))
-URI http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756

Reference 15: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 9
-URI http://asc.fasb.org/extlink&oid=124431687&loc=d3e22663-107794

Reference 16: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(iv))
-URI http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756

Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(ii))
-URI http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756

Reference 18: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 825
-SubTopic 10
-Section 50
-Paragraph 28
-Subparagraph (f)
-URI http://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612

Reference 19: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=124431687&loc=d3e22583-107794

Reference 20: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(g)(1)(ii))
-URI http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690

Reference 21: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 60B
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=125511455&loc=SL5780133-109256

Reference 22: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 323
-SubTopic 10
-Section 50
-Paragraph 3
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571

Reference 23: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 8
-URI http://asc.fasb.org/extlink&oid=124431687&loc=d3e22658-107794

Reference 24: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 1A
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=124509347&loc=SL7669619-108580

Reference 25: http://www.xbrl.org/2003/role/exampleRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 31
-URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e8924-108599

Reference 26: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 11
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794

Reference 27: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 11
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794

Reference 28: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 7
-URI http://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760

Reference 29: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 1B
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=124509347&loc=SL7669625-108580

Reference 30: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 22
-URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599

Reference 31: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(5))
-URI http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756

Reference 32: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(iii)(B))
-URI http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756

Reference 33: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(iii)(A))
-URI http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756

Reference 34: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 30
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599

Reference 35: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599

+ Details

Net Loss Per Share (Tables)

12 Months Ended

Dec. 31, 2021

Earnings Per Share [Abstract]

Schedule of Antidilutive Securities Excluded in Calculation of Diluted Net Loss Per Share

The following table sets forth the outstanding, potentially dilutive securities that have been excluded in the calculation of diluted net loss per share because their inclusion would be anti-dilutive:


	December 31, 2021		December 31, 2020
Convertible preferred stock	$	—	$	13,504,598
Stock options		2,673,775		1,601,214
Shares subject to repurchase		239,826		646,953
Employee stock purchase plan		3,833		—
Total	$	2,917,434	$	15,752,765

Convertible Preferred Stock and Stockholders' Deficit - Summary of Restricted Shares of Common Stock and Unvested Stock Liability (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
Liabilities And Stockholders Equity [Line Items]
Beginning Balance, Unvested stock liability	$ 145	$ 1
Shares early exercised, unvested stock liability		145
Vested shares, Unvested stock liability	(122)	1
Ending Balance, Unvested stock liability	$ 23	$ 145
Restricted Shares
Liabilities And Stockholders Equity [Line Items]
Beginning Balance	646,953	811,268
Shares early exercised		153,373
Vested shares	(407,127)	(317,688)
Ending Balance	239,826	646,953

Balance Sheet Details (Tables)

12 Months Ended

Dec. 31, 2021

Organization Consolidation And Presentation Of Financial Statements [Abstract]

Summary of Prepaid Expenses and Other Current Assets

Prepaid expenses and other current assets consisted of the following (in thousands):


	December 31, 2021		December 31, 2020
Prepaid expenses	$	1,254	$	60
Security deposits		—		47
Interest receivable		110		10
Other		7		25
Total	$	1,371	$	142

Summary of Property and Equipment

Property and equipment consisted of the following (in thousands):


	December 31, 2021			December 31, 2020
Laboratory equipment	$	1,148		$	76
Computer equipment and software		96			—
Furniture and fixtures		292			—
Leasehold improvements		95			—
Construction in progress		11			—
		1,642			76
Less accumulated depreciation		(134	)		(5	)
Total	$	1,508		$	71

Summary of Accrued Liabilities

Accrued liabilities consisted of the following (in thousands):


	December 31, 2021		December 31, 2020
Accrued personnel costs	$	2,152	$	565
Accrued research and development costs		516		266
Current portion of operating lease liability, related party		489		—
Accrued other		506		100
Total	$	3,663	$	931

Investment Securities - Additional Information (Details)	Dec. 31, 2021 USD ($) Security	Dec. 31, 2020 USD ($) Security
Schedule Of Available For Sale Securities [Line Items]
Number of available-for-sale investment securities in continuous unrealized loss position, less than 12 months \| Security	38	0
Number of domestic certificates of deposit held \| Security	24
Accrued interest receivable on available-for-sale investment securities \| $	$ 100,000
Maximum
Schedule Of Available For Sale Securities [Line Items]
Accrued interest receivable on available-for-sale investment securities \| $		$ 100,000

Employee Benefit Plans	12 Months Ended
Employee Benefit Plans	Dec. 31, 2021
Retirement Benefits [Abstract]
Employee Benefit Plans	15. Employee Benefit Plans The Company maintains a retirement plan, which is qualified under section 401(k) of the Internal Revenue Code of 1986, as amended, for the Company's U.S. employees. The plan allows eligible employees to defer, at the employee's discretion, pretax compensation up to the IRS annual limits. The Company is not required to make matching contributions under the plan and had not made any such contributions as of December 31, 2021.

Fair Value Measurements - Summary of Financial Instruments Measured at Fair Value on Recurring Basis (Details) - USD ($) $ in Thousands	Dec. 31, 2021	Dec. 31, 2020
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Investments, fair value disclosure	$ 383,609	$ 35,812
Money market funds
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Investments, fair value disclosure	298,114	2,100
Certificates of deposit
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Investments, fair value disclosure	5,771	1,754
U.S. Treasury securities
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Investments, fair value disclosure	79,724	31,958
Quoted Prices in Active Markets for Identical Assets (Level 1)
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Investments, fair value disclosure	383,609	35,812
Quoted Prices in Active Markets for Identical Assets (Level 1) \| Money market funds
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Investments, fair value disclosure	298,114	2,100
Quoted Prices in Active Markets for Identical Assets (Level 1) \| Certificates of deposit
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Investments, fair value disclosure	5,771	1,754
Quoted Prices in Active Markets for Identical Assets (Level 1) \| U.S. Treasury securities
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Investments, fair value disclosure	$ 79,724	$ 31,958

Organization and Description of Business - Additional Information (Details) $ / shares in Units, $ in Thousands	1 Months Ended		12 Months Ended
	Mar. 31, 2021 USD ($) $ / shares shares	Feb. 29, 2020	Dec. 31, 2021 USD ($)	Dec. 31, 2020 USD ($)
Subsidiary, Sale of Stock [Line Items]
Stock split of issued and outstanding common stock			5-for-1
Reverse stock split of issued and outstanding common stock			1-for-1.63
Conversion ratio of forward/reverse stock split	0.613497	5
Accumulated deficit \| $			$ 47,456	$ 11,923
Cash, cash equivalents and investment securities \| $			$ 384,100
Initial Public Offering
Subsidiary, Sale of Stock [Line Items]
Initial public offering of common shares \| shares	13,800,000
Share price \| $ / shares	$ 20.00
Proceeds from sale of common stock \| $	$ 254,300
Preferred stock converted into shares of common stock \| shares	41,096,478
Preferred stock converted into shares of common stock, Shares \| shares	25,212,548

Organization and Description of Business

12 Months Ended

Dec. 31, 2021

Accounting Policies [Abstract]

Organization and Description of Business

1. Organization and Description of Business

Description of Business

Design Therapeutics, Inc. (the “Company”) was incorporated in Delaware in December 2017 and is based in Carlsbad, California. The Company is a preclinical-stage biopharmaceutical company pioneering GeneTACTM molecules, which are a novel class of small-molecule gene targeted chimera therapeutics that are designed to be disease-modifying and target the underlying cause of inherited nucleotide repeat expansion diseases. The Company’s lead product candidate is in Friedreich ataxia (“FA”), its second GeneTAC™ program is in myotonic dystrophy type-1 (“DM1”), and it is also advancing its GeneTACTM portfolio to address other serious nucleotide repeat-driven monogenic diseases.

Stock Splits

In February 2020, the Company effected a 5-for-1 forward stock split of its issued and outstanding common stock. Further, in March 2021, the Company effected a 1-for-1.63 reverse stock split of its issued and outstanding common stock. The par value and the authorized shares of the common stock were not adjusted as a result of these stock splits. The reverse stock split in March 2021 resulted in an adjustment to the convertible preferred stock conversion prices to reflect a proportional decrease in the number of shares of common stock to be issued upon conversion. The accompanying financial statements and notes to the financial statements give retroactive effect to the stock splits for all periods presented.

Initial Public Offering

In March 2021, the Company completed its IPO selling 13,800,000 shares its common stock at $20.00 per share. Proceeds from the Company’s IPO, net of underwriting discounts and commissions and other offering costs, were $254.3 million. In connection with the IPO, all 41,096,478 shares of convertible preferred stock outstanding at the time of the IPO converted into 25,212,548 shares of the Company’s common stock.

Liquidity and Capital Resources

The accompanying financial statements have been prepared assuming that the Company will continue as a going concern, which contemplates the realization of assets and the satisfaction of liabilities in the normal course of business. The Company has incurred net operating losses since inception and had an accumulated deficit of $47.5 million as of December 31, 2021. The Company had cash, cash equivalents and investment securities of $384.1 million as of December 31, 2021, and has not generated positive cash flows from operations.

Management expects to incur net losses for the foreseeable future. There can be no assurance that the Company will ever earn revenues or achieve profitability, or if achieved, that they will be sustained on a continuing basis. In addition, the preclinical manufacturing, and clinical development activities as well as the commercialization of the Company’s products, if approved, will require significant additional financing. The Company may be unable to secure such financing when needed, or if available, such financings may be under terms that are unfavorable to the Company or the current stockholders. If the Company is unable to raise additional funds when needed, it may be required to delay, reduce the scope of, or eliminate development programs, which may adversely affect its business and operations. The Company’s currently available cash and cash equivalents as of December 31, 2021 are sufficient to meet its anticipated cash requirements for more than the 12 months following the date the financial statements are issued.

Commitments and Contingencies - Additional Information (Details) - USD ($) $ / shares in Units, $ in Millions	1 Months Ended			12 Months Ended
	Feb. 29, 2020	Nov. 30, 2019	Jan. 31, 2019	Dec. 31, 2021	Jan. 31, 2020	Dec. 31, 2019	Mar. 31, 2019	Feb. 28, 2019
Commitments And Contingencies Disclosure [Line Items]
Debt instrument interest rate								8.00%
Convertible notes issued								$ 0.2
Percentage of selling price per share that can convertible into equity securities sold								80.00%
Converted amount	$ 0.5
Series A Convertible Preferred Stock
Commitments And Contingencies Disclosure [Line Items]
Converted shares	301,685
Share price	$ 1.65816
May 2018 Note
Commitments And Contingencies Disclosure [Line Items]
Maturity description				on or after February 5, 2021, if not converted earlier
July 2018 Note
Commitments And Contingencies Disclosure [Line Items]
Maturity description				on or after February 5, 2021, if not converted earlier
February 2019 Note
Commitments And Contingencies Disclosure [Line Items]
Maturity description				on or after May 16, 2020, if not converted earlier
Unsecured Promissory Note \| January Note
Commitments And Contingencies Disclosure [Line Items]
Maturity description				on or before January 30, 2021
Percentage of final payment on advanced at maturity			3.00%
Debt instrument interest rate							10.00%	10.00%
Unsecured Promissory Note \| January Note \| Maximum
Commitments And Contingencies Disclosure [Line Items]
Notes issued			$ 0.5
Unsecured Promissory Note \| January Note \| Prime Plus
Commitments And Contingencies Disclosure [Line Items]
Debt instrument variable interest rate			4.50%
Unsecured Promissory Note \| November Note
Commitments And Contingencies Disclosure [Line Items]
Maturity description				on or before January 1, 2022
Percentage of final payment on advanced at maturity		3.00%
Debt instrument interest rate					9.25%	9.25%
Unsecured Promissory Note \| November Note \| Maximum
Commitments And Contingencies Disclosure [Line Items]
Notes issued		$ 0.5
Unsecured Promissory Note \| November Note \| Prime Plus
Commitments And Contingencies Disclosure [Line Items]
Debt instrument variable interest rate		4.50%
Unsecured Promissory Note \| February and March 2019 Draws \| January Note
Commitments And Contingencies Disclosure [Line Items]
Borrowings				$ 0.2
Unsecured Promissory Note \| Jan 2020 and Dec 2019 Draws \| November Note
Commitments And Contingencies Disclosure [Line Items]
Borrowings				0.4
Convertible Notes Issued in May and July 2018
Commitments And Contingencies Disclosure [Line Items]
Convertible notes issued				$ 0.3

Statements of Operations (Parenthetical) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
Income Statement [Abstract]
Research and development expenses related party amount	$ 405	$ 53
General and administrative expenses related party amount	328	292
Other income, net related party expense amount	$ 0	$ 30

Related Party Transactions (Tables)

12 Months Ended

Dec. 31, 2021

Consulting Agreements

Summary of Expenses Recognized under Various Agreements

Expenses recognized by the Company under the 2020 Consulting Agreement during the periods presented were as follows (in thousands):


	Year Ended December 31,
	2021		2020
Research and development	$	—	$	8
General and administrative		240		292
Total expenses	$	240	$	300

Research Consulting Agreements

Summary of Expenses Recognized under Various Agreements

Expenses recognized by the Company under the Research Consulting Agreement during the periods presented were as follows (in thousands):


	Year Ended December 31,
	2021		2020
Research and development	$	180	$	45
Total expenses	$	180	$	45

Lease Agreement

Summary of Expenses Recognized under Various Agreements

Expenses recognized by the Company under the Lease during the periods presented were as follows (in thousands):


	Year Ended December 31,
	2021		2020
Research and development	$	225	$	—
General and administrative		88		—
Total expenses	$	313	$	—

Income Taxes - Additional Information (Details) - USD ($)	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
Operating Loss Carryforwards [Line Items]
Accrued interest or penalties	$ 0	$ 0
Recognized interest or penalties	0	$ 0
Federal
Operating Loss Carryforwards [Line Items]
Net operating loss carryforwards	40,300,000
Net operating loss carryforwards, subject to expiration	100,000
Net operating loss carryforwards, not subject to expiration	$ 40,200,000
Net operating loss carryforward, expiration year	2037
NOL, percent of taxable income	80.00%
Federal \| Research and Development Credit Carryforwards
Operating Loss Carryforwards [Line Items]
Tax credit carryforwards	$ 900,000
Tax credit carryforwards, expiration year	2038
State
Operating Loss Carryforwards [Line Items]
Net operating loss carryforwards	$ 10,400,000
Net operating loss carryforward, expiration year	2037
State \| Research and Development Credit Carryforwards
Operating Loss Carryforwards [Line Items]
Tax credit carryforwards	$ 600,000

Fair Value Measurements (Tables)

12 Months Ended

Dec. 31, 2021

Fair Value Disclosures [Abstract]

Summary of Company's Financial Instruments Measured at Fair Value on a Recurring Basis

The following table summarizes the Company’s financial instruments measured at fair value on a recurring basis at December 31, 2021 and 2020 (in thousands):


	Fair Value Measurement at End of Period Using:
			Quoted Prices
			In Active
			Markets		Significant
			For		Other		Significant
			Identical		Observable		Unobservable
			Assets		Inputs		Inputs
	Total		(Level 1)		(Level 2)		(Level 3)
As of December 31, 2021:
Assets:
Money market funds(1)	$	298,114	$	298,114	$	—	$	—
Certificates of deposit		5,771		5,771		—		—
U.S. Treasury securities		79,724		79,724		—		—
Total	$	383,609	$	383,609	$	—	$	—
As of December 31, 2020:
Assets:
Money market funds(1)	$	2,100	$	2,100	$	—	$	—
Certificates of deposit		1,754		1,754		—		—
U.S. Treasury securities		31,958		31,958		—		—
Total	$	35,812	$	35,812	$	—	$	—

(1)

Included in cash and cash equivalents on the accompanying balance sheets.

Related Party Transactions

12 Months Ended

Dec. 31, 2021

Related Party Transactions

14. Related Party Transactions

Lease Agreement

In February 2021, the Company entered into the Lease with Crossing Holdings, LLC to rent laboratory and office space. The Company's Executive Chairperson, co-founder and member of its board of directors, is the sole member and Manager of Crossing Holdings, LLC.

Expenses recognized by the Company under the Lease during the periods presented were as follows (in thousands):


	Year Ended December 31,
	2021		2020
Research and development	$	225	$	—
General and administrative		88		—
Total expenses	$	313	$	—

Consulting Agreements

In January 2019, the Company entered into an agreement with the Marlinspike Group, LLC (“Marlinspike Group”) for research support, management, and business consulting services (the “2019 Consulting Agreement”).

Further, Marlinspike Group provides the use of approximately 2,120 square feet of its office space in Carlsbad, California to the Company on an as-available basis from time to time pursuant to the agreement. The Company’s Executive Chairperson, co-founder and member of its board of directors is an executive officer of Marlinspike Group and, the Company’s Chief Operating Officer was an executive officer of Marlinspike Group until February 2020.

The term of the 2019 Consulting Agreement was for a one-year period, subject to automatic one-month renewals unless terminated upon 14 days’ written notice. In March 2020, the Consulting Agreement was terminated and replaced with an amended consulting agreement (the “2020 Consulting Agreement”), which provides for the similar services and use of office space for a monthly fee of $20,000. Pursuant to the terms of the 2020 Consulting Agreement, it shall remain in effect until otherwise terminated. Termination may occur at any time upon mutual agreement or unilaterally upon 30 days’ written notice. If the Company unilaterally terminates the 2020 Consulting Agreement for any reason other than cause, it would be subject to a $0.2 million termination fee. The Company cannot determine when, or if, such a termination will occur and hence has not recorded a liability for the fee.

Expenses recognized by the Company under the 2020 Consulting Agreement during the periods presented were as follows (in thousands):


	Year Ended December 31,
	2021		2020
Research and development	$	—	$	8
General and administrative		240		292
Total expenses	$	240	$	300

In December 2017, the Company entered into a consulting agreement with Aseem Z. Ansari, Ph.D. Dr. Asnsari, a co-founder, provides consulting services and advises on certain research and development activities (the “Research Consulting Agreement”). Pursuant to the Research Consulting Agreement, as amended, Dr. Ansari performs these services for a monthly fee of $15,000.

Expenses recognized by the Company under the Research Consulting Agreement during the periods presented were as follows (in thousands):


	Year Ended December 31,
	2021		2020
Research and development	$	180	$	45
Total expenses	$	180	$	45

The Company had accrued expenses and other current liabilities of $15,000 as of December 31, 2021 and accounts payable of $20,000 as of December 31, 2020, pursuant to its related party consulting agreements.

Convertible Notes and Notes Payable

In May and July 2018, the Company issued a total of $0.3 million of convertible notes to a co-founder for cash with a maturity date on or after February 5, 2021, if not converted earlier. The notes bore interest of 8% per annum and were convertible into equity securities sold at the next financing at 80% of the selling price per share of such equity financing. In February 2020, these notes converted into 171,025 shares of the Company’s convertible preferred stock pursuant to the closing of the Series A preferred stock financing. Further, the Company has issued unsecured promissory notes to this co-founder for working capital. See Note 12 for further discussion.

Lease - Additional Information (Details) $ in Millions	1 Months Ended		12 Months Ended
Lease - Additional Information (Details) $ in Millions	Sep. 30, 2021	Feb. 28, 2021 ft²	Dec. 31, 2021 USD ($)	Dec. 31, 2020 USD ($)
Lessee, Lease, Description [Line Items]
Lease agreement termination date	2021-09
Rent expense \| $			$ 0.6	$ 0.1
Crossing Holdings, LLC
Lessee, Lease, Description [Line Items]
Area of lease space \| ft²		12,370
Lease commencement date			2021-09
Lease term		72 months
Option to renew lease term ends, year			2027
Lessee, Operating Lease, Existence of Option to Extend [true false]		true
Lease term, option to extend period			three years
Percentage of annual increase in lease payments		3.00%
Operating lease remaining lease term			5 years 8 months 12 days
Operating lease right-of-use asset discount rate			7.15%

Net Loss Per Share - Schedule of Antidilutive Securities Excluded in Calculation of Diluted Net Loss Per Share (Details) - shares	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive securities excluded from calculation of diluted net loss per share	2,917,434	15,752,765
Convertible Preferred Stock
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive securities excluded from calculation of diluted net loss per share		13,504,598
Stock Options
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive securities excluded from calculation of diluted net loss per share	2,673,775	1,601,214
Shares Subject to Repurchase
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive securities excluded from calculation of diluted net loss per share	239,826	646,953
Employee Stock Purchase Plan
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive securities excluded from calculation of diluted net loss per share	3,833

License Agreement

12 Months Ended

Dec. 31, 2021

License Agreement [Abstract]

License Agreement

13. License Agreement

In February 2019, the Company entered into a Human Therapeutics Exclusive License Agreement (the “License Agreement”) with the Wisconsin Alumni Research Foundation (“WARF”). Under the License Agreement, the Company licensed the exclusive, worldwide, royalty-bearing, sublicensable rights to certain WARF patents and the nonexclusive worldwide rights to certain know-how to develop and commercialize products for the prevention, diagnosis and treatment of disease. As consideration for the license, the Company agreed to pay an upfront fee of $250,000, which the Company immediately expensed as research and development expense in its statements of operations as there was no alternative future use for the license. The Company paid $25,000 of the upfront fee upon execution of the agreement and the remaining $225,000 was due upon the earlier of the first anniversary of the License Agreement or the Company receiving a certain level of gross proceeds from an equity financing. In February 2020, the Company paid the $225,000 balance upon the initial closing of its Series A preferred stock financing.

Pursuant to the License Agreement, the Company is required to pay $125,000 upon the acceptance of an investigation new drug (“IND”) application in the U.S. and will be required to make further aggregate milestone payments of up to $17.5 million upon achievement of certain other regulatory and commercial milestones. The Company may also be required to pay royalties based on annual net product sales in the low single digits on its or its sublicensees’ net product sales on a country-by-country and product-by-product basis, and is subject to a minimum royalty of $0.1 million per calendar year upon first commercial product sale. Further, the Company may be required to pay sublicense fees in the mid-single digits percentage for fees, royalties or other payments earned from the granting of sublicenses to the WARF patents and know-how. The Company has paid no milestone or royalty payments as of December 31, 2021.

The Company is responsible for reimbursing WARF for costs incurred in connection with prosecuting and maintaining patent rights that are specific to the License Agreement. Expenses recognized in connection with legal patent fees under this License Agreement were $0.1 million for the year ended December 31, 2021 and less than $0.1 million for the year ended December 31, 2020, which were recorded as general and administrative expenses in the statements of operations.

The Company may terminate the License Agreement with 90 days written notice or for certain breaches of the agreement. WARF may terminate the License Agreement with 90 days written notice if first commercial sale does not occur before December 31, 2031. Unless terminated earlier by the parties, the term of the License Agreement will continue until the last licensed patent expires in all countries.

Related Party Transactions - Additional Information (Details)	1 Months Ended				12 Months Ended
	Mar. 31, 2020 USD ($)	Feb. 29, 2020 shares	Jan. 31, 2019 ft²	Dec. 31, 2017 USD ($)	Dec. 31, 2021 USD ($)	Dec. 31, 2020 USD ($)	Feb. 28, 2019 USD ($)	Jul. 31, 2018 USD ($)	May 31, 2018 USD ($)
Related Party Transaction [Line Items]
Accrued expenses and other current liabilities, related party amounts					$ 504,000	$ 0
Convertible notes issued							$ 200,000
Debt instrument interest rate							8.00%
Percentage of selling price per share that can convertible into equity securities sold							80.00%
Consulting Agreements
Related Party Transaction [Line Items]
Accrued expenses and other current liabilities, related party amounts					$ 15,000
Accounts payable						$ 20,000
Marlinspike Group, LLC \| 2020 Consulting Agreement
Related Party Transaction [Line Items]
Monthly fee for consultancy services	$ 20,000
Termination fee	$ 200,000
Marlinspike Group, LLC \| Carlsbad, California \| 2019 Consulting Agreement
Related Party Transaction [Line Items]
Area of office space \| ft²			2,120
Aseem Z. Ansari, Ph.D. \| Convertible Notes and Notes Payable
Related Party Transaction [Line Items]
Convertible notes issued								$ 300,000	$ 300,000
Debt instrument interest rate									8.00%
Percentage of selling price per share that can convertible into equity securities sold									80.00%
Aseem Z. Ansari, Ph.D. \| Convertible Notes and Notes Payable \| Series A Preferred Stock
Related Party Transaction [Line Items]
Convertible preferred stock converted \| shares		171,025
Aseem Z. Ansari, Ph.D. \| May Note
Related Party Transaction [Line Items]
Maturity description					on or after February 5, 2021, if not converted earlier
Aseem Z. Ansari, Ph.D. \| July Note
Related Party Transaction [Line Items]
Maturity description					on or after February 5, 2021, if not converted earlier
Aseem Z. Ansari, Ph.D. \| Consulting Agreements
Related Party Transaction [Line Items]
Monthly fee for services				$ 15,000

Statements of Cash Flows - USD ($) $ in Thousands	12 Months Ended
Statements of Cash Flows - USD ($) $ in Thousands	Dec. 31, 2021	Dec. 31, 2020
Cash flows from operating activities
Net loss	$ (35,533)	$ (8,280)
Reconciliation of net loss to net cash used in operating activities:
Depreciation	129	5
Stock-based compensation	4,689	450
Amortization of premiums on investment securities, net	(77)	(71)
Non-cash interest expense		12
Non-cash interest expense—related party		26
Net change in operating lease right-of-use assets and liabilities-related party	19
Change in operating assets and liabilities:
Prepaid expense and other assets	(1,017)	(341)
Deferred revenue		(201)
Accounts payable and other liabilities	2,418	1,430
Accounts payable and other liabilities related-party	(5)	(1,843)
Other long-term liabilities		144
Net cash used in operating activities	(29,377)	(8,669)
Cash flows from investing activities
Purchases of investment securities	(86,261)	(55,589)
Proceeds from maturities of investment securities	34,155	22,104
Purchases of property and equipment	(1,538)	(76)
Net cash used in investing activities	(53,644)	(33,561)
Cash flows from financing activities
Proceeds from initial public offering, net of issuance costs	254,271
Proceeds from issuance of convertible preferred stock, net of issuance costs	124,712	44,731
Issuance of common stock through employee stock purchase plan	194
Proceeds from the exercise of stock options	34	1
Proceeds from the issuance of notes payable, net of issuance costs—related party		200
Repayment of notes payable—related party		(400)
Net cash provided by financing activities	379,211	44,532
Net increase in cash and cash equivalents	296,190	2,302
Cash and cash equivalents at beginning of period	2,379	77
Cash and cash equivalents at end of period	298,569	2,379
Supplemental disclosures
Initial recognition of operating lease right-of-use asset and operating lease liability	3,786
Purchases of property and equipment included in accrued expenses	$ 29
Conversion of convertible notes to convertible preferred shares, including bifurcated conversion liability		271
Conversion of convertible notes to convertible preferred shares, including bifurcated conversion liability - related party		354
Interest paid		$ 24

Summary of Significant Accounting Policies (Policies)	12 Months Ended
Summary of Significant Accounting Policies (Policies)	Dec. 31, 2021
Accounting Policies [Abstract]
Basis of Presentation and Use of Estimates	Basis of Presentation and Use of Estimates The financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (GAAP). The preparation of financial statements in conformity with GAAP requires the Company to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of product sales and expense during the reporting period. Although these estimates are based on the Company’s knowledge of current events and anticipated actions it may undertake in the future, actual results may ultimately materially differ from these estimates and assumptions. The preparation of the Company’s financial statements requires it to make estimates and assumptions that impact the reported amounts of assets, liabilities, revenues and expenses and the disclosure of contingent assets and liabilities in the Company’s financial statements and accompanying notes. The most significant estimates in the Company’s financial statements relate to the recognition of grant revenue, accruals for research and development expenses and the valuation of equity-based awards. These estimates and assumptions are based on current facts, historical experience and various other factors believed to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities and the recording of revenue and expenses that are not readily apparent from other sources. Actual results may differ materially and adversely from these estimates. The full extent to which the novel coronavirus-2019 (“COVID-19”) pandemic will directly or indirectly impact the Company’s business, results of operations and financial condition, including research and development costs, will depend on future developments that are highly uncertain, including as a result of new information that may emerge concerning COVID-19 and the actions taken to contain or treat COVID-19, as well as the economic impact on local, regional, national and international markets. The Company has considered potential impacts arising from the COVID-19 pandemic and is not presently aware of any events or circumstances that would require the Company to update its estimates, judgments or revise the carrying value of its assets or liabilities.
Segment Reporting	Segment Reporting Operating segments are identified as components of an enterprise about which separate discrete financial information is available for evaluation by the chief operating decision-maker in making decisions regarding resource allocation and assessing performance. The Company manages its operations as a single reportable segment for the purposes of assessing performance and making operating decisions.
Concentration of Credit Risk	Concentrations of Credit Risk Financial instruments that potentially subject the Company to significant concentrations of credit risk consist primarily of cash, cash equivalents and investment securities. The Company maintains deposits in federally insured financial institutions in excess of federally insured limits. The Company has not experienced any losses in such accounts and believes it is not exposed to significant risk on its cash balances due to the financial position of the depository institution in which those deposits are held. Additionally, the Company has established guidelines regarding approved investments and maturities of investments, which are designed to maintain safety and liquidity.
Cash and Cash Equivalents	Cash and Cash Equivalents The Company considers all highly liquid investments with maturities at the date of acquisition of three months or less to be cash equivalents. These investments may include money market accounts, money market funds, U.S. Government agency securities, corporate debt securities and commercial paper. The carrying amounts approximate fair value due to the short maturities of these instruments. The Company’s cash reserves are in a readily available checking account.
Investment Securities	Investment Securities Investments in securities with maturities at the date of acquisition of more than three months are considered marketable securities. These investments may include money market accounts, money market funds, certificates of deposits, U.S. Treasury securities, and high quality, marketable debt instruments of corporations and government sponsored enterprises. The Company determines the appropriate classification of its investments at the time of acquisition and reevaluates such determination at each balance sheet date. The Company has classified its investment holdings as available-for-sale, as the sale of such securities may be required prior to maturity to implement management strategies. Further, the Company classifies its available-for-sale investment securities, including those with maturities beyond one year, as current assets on its balance sheets based on the highly liquid nature of the securities and because these investments are considered available for use in current operations. The Company’s investment policy sets minimum credit quality criteria and maximum maturity limits on its investments to provide for safety of principle, liquidity and a reasonable rate of return. Available-for-sale securities are recorded at fair value, based on current market valuations. Unrealized holding gains and losses on available-for-sale securities are excluded from earnings and are reported as a separate component of other comprehensive income (loss) until realized. Allowances for credit losses are reported on the balance sheet, if any. The cost of available-for-sale investment securities is adjusted for amortization of premiums and accretion of discounts until the securities mature. Such amortization and accretion is included in other income, net on the statements of operations. Realized gains and losses, if any, are also included in other income, net on the statement of operations and are derived using the specific identification method for determining the cost of the securities sold. During the periods presented, no realized gains or losses were recorded on the sale of investment securities and no impairments to reduce the value of any security was taken. See Note 5 for further discussion.
Property and Equipment, Net	Property and Equipment, Net Property and equipment generally consist of laboratory equipment, computer equipment and software, and furniture and fixtures and are recorded at cost and depreciated using the straight-line method over the estimated useful lives of the assets (generally three to five years). Leasehold improvements are recorded at cost and are depreciated on a straight-line basis over the lesser of the remaining term of the related lease or the estimated useful lives of the assets. Repairs and maintenance costs are charged as incurred. An impairment loss is recorded if and when events and circumstances indicate that assets might be impaired and the undiscounted cash flows estimated to be generated by those assets are less than the carrying amount of those assets. The Company has not recognized any impairment losses for the years ended December 31, 2021 and 2020.
Leases	Leases Leases consist of an operating lease the Company has related to its facility. At lease commencement, the Company records a lease liability based on the present value of lease payments over the expected lease term. The expected lease term includes noncancelable lease periods and, when applicable, periods covered by an option to extend the lease if the Company is reasonably certain to exercise that option, as well as periods covered by an option to terminate the lease if the Company is reasonably certain not to exercise the option. For those leases where the implicit rate is not provided, the Company calculates the present value of lease payments using an incremental borrowing rate. The Company's incremental borrowing rate for a lease is the rate of interest it would have to pay on a collateralized basis to borrow an amount equal to the lease payments under similar terms. At the lease commencement date, the Company records a corresponding right-of-use ("ROU") lease asset based on the lease liability, adjusted for any lease incentives received and any initial direct costs paid to the lessor prior to the lease commencement date. The Company may enter into leases with an initial term of 12 months or less ("Short-Term Leases"). For any Short-Term leases, the Company records the rent expense on a straight-line basis and ROU asset and lease obligations are not recognized. The Company had no Short-Term Leases as of December 31, 2021 or 2020. After lease commencement, the Company measures its leases as follows: (i) the lease liability based on the present value of the remaining lease payments using the discount rate determined at lease commencement and (ii) the ROU asset based on the remeasured lease liability, adjusted for any unamortized lease incentives received, any unamortized initial direct costs and the cumulative difference between rent expense and amounts paid under the lease agreement. Any lease incentives received and any initial direct costs are amortized on a straight-line basis over the expected lease term. Rent expense is recorded on a straight-line basis over the expected lease term.
Research and Development Expenses	Research and Development Expenses Research and development expenses consist of costs incurred in connection with the Company's discovery efforts, and the preclinical and formulation development of its product candidates. Research and development expenses are charged to operating expenses as incurred.
Patent Costs	Patent Costs Costs related to filing and pursuing patent applications are recorded as general and administrative expenses in the statements of operations and expensed as incurred since recoverability of such expenditures is uncertain.
Stock-Based Compensation	Stock-Based Compensation Stock options and restricted stock issued pursuant to the Company’s 2021 Equity Incentive Plan (the “2021 Plan”) and 2018 Equity Incentive Plan (the “2018 Plan”), and option features associated with the rights to purchase shares pursuant to the Company’s 2021 Employee Stock Purchase Plan (the “ESPP”) are valued using the Black-Scholes option pricing model on the date of grant or subscription period. This option pricing model involves a number of estimates, including the expected lives of the stock options or subscription period, the Company's anticipated stock volatility and interest rates. The Company recognizes the expense for equity awards on a straight-line basis over the requisite service periods of the awards or the number of shares estimated to be issued pursuant to the ESPP. Forfeitures are recognized as they occur.
Income Taxes	Income Taxes The Company uses the asset and liability method of accounting for income taxes. Under this method, deferred tax assets and liabilities are determined based on the difference between the financial reporting and the tax reporting basis of assets and liabilities and are measured using the enacted tax rates and laws that are expected to be in effect when the differences are expected to reverse. The Company provides a valuation allowance against net deferred tax assets unless, based upon the available evidence, it is more likely than not that the deferred tax assets will be realized. When the Company establishes or reduces the valuation allowance against its deferred tax assets, its provision for income taxes will increase or decrease, respectively, in the period such determination is made. The accounting guidance for uncertainty in income taxes prescribes a recognition threshold and measurement attribute criteria for the financial statement recognition and measurement of tax positions taken or expected to be taken in a tax return. For those benefits to be recognized, a tax position must be more likely than not to be sustained upon examination by taxing authorities based on the technical merits of the position.

Stock-Based Compensation - Weighted-Average Assumptions Used in Black-Scholes Option Pricing Model to Determine Fair Value of Stock Option Grants (Details) - $ / shares	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Fair value of common stock	$ 15.60	$ 5.08
Expected term (years)	6 years 25 days	6 years 3 months 25 days
Expected volatility	72.83%	72.93%
Risk-free interest rate	1.04%	0.62%
Expected dividend yield	0.00%	0.00%
2021 Employee Stock Purchase Plan
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Fair value of common stock	$ 19.96
Expected term (years)	1 year 4 months 28 days
Expected volatility	69.26%
Risk-free interest rate	0.18%
Expected dividend yield	0.00%

Convertible Preferred Stock and Stockholders' Deficit (Tables)

12 Months Ended

Dec. 31, 2021

Equity [Abstract]

Summary of Restricted Shares of Common Stock and Unvested Stock Liability

A summary of the Company’s restricted shares of common stock and unvested stock liability, which is included in accrued expenses and other current liabilities and other long-term liabilities on the Company’s balance sheets, is as follows (in thousands, except share data):


	Shares			Liability
Balance at December 31, 2019		811,268		$	1
Shares early exercised		153,373			145
Vested shares		(317,688	)		(1	)
Balance at December 31, 2020		646,953			145
Vested shares		(407,127	)		(122	)
Balance at December 31, 2021		239,826		$	23

Convertible Preferred Stock and Stockholders' Deficit - Additional Information (Details) - USD ($) $ / shares in Units, $ in Thousands		1 Months Ended				12 Months Ended
	Mar. 25, 2021	Mar. 31, 2021	Jan. 31, 2021	Mar. 31, 2020	Feb. 29, 2020	Dec. 31, 2021	Dec. 31, 2020
Convertible Preferred Stock And Stockholders Deficit [Line Items]
Common stock, shares authorized						200,000,000	60,000,000
Common stock, par value						$ 0.0001	$ 0.0001
Convertible preferred stock, issued						0	22,012,499
Convertible preferred stock, par value						$ 0.0001	$ 0.0001
Proceeds from issuance of convertible preferred stock, net of issuance costs						$ 124,712	$ 44,731
2021 Equity Incentive Award Plan
Convertible Preferred Stock And Stockholders Deficit [Line Items]
Common stock reserved for issuance	6,118,648
Common stock remained available for issuance						6,079,984
Common stock issuance, description and terms						the number of shares of common stock available for issuance under the 2021 Plan will automatically increase on January 1 of each calendar year, starting on January 1, 2022 through January 1, 2031, in an amount equal to 5% of the total number of shares outstanding of the Company’s common stock on the last day of the calendar month before the date of each automatic increase, or a lesser number of shares determined by the Company’s board of directors.
2018 Equity Incentive Plan
Convertible Preferred Stock And Stockholders Deficit [Line Items]
Common stock remained available for issuance	881,352
2021 Employee Stock Purchase Plan
Convertible Preferred Stock And Stockholders Deficit [Line Items]
Common stock reserved for issuance	600,000					588,544
Common stock remained available for issuance	1,200,000
Common stock issuance, description and terms						the number of shares of common stock available for issuance under the ESPP will automatically increase on January 1 of each calendar year, starting on January 1, 2022 through January 1, 2031, in an amount equal to the lesser of (i) 1% of the total number of shares outstanding of the Company’s common stock on the last day of the calendar month before the date of each automatic increase and (ii) 1,200,000 shares; provided that before the date of any such increase, the Company’s board of directors may determine that such increase will be less than the amount set forth in clauses (i) and (ii).
Maximum percentage of eligible earnings withheld to participate in offering	15.00%
Price of common stock purchased	85.00%
Series A Convertible Preferred Stock
Convertible Preferred Stock And Stockholders Deficit [Line Items]
Share price					$ 1.65816
Convertible preferred stock, issued				21,710,814	21,710,814
Convertible preferred stock, par value				$ 2.0727	$ 2.0727
Proceeds from issuance of convertible preferred stock, net of issuance costs				$ 44,700	$ 44,700
Converted shares					301,685
Series B Convertible Preferred Stock
Convertible Preferred Stock And Stockholders Deficit [Line Items]
Convertible preferred stock, issued			19,083,979
Convertible preferred stock, par value			$ 6.55
Proceeds from issuance of convertible preferred stock, net of issuance costs			$ 124,700
Common Stock \| 2018 Equity Incentive Plan \| Restricted Shares
Convertible Preferred Stock And Stockholders Deficit [Line Items]
Vesting period						4 years
Initial Public Offering
Convertible Preferred Stock And Stockholders Deficit [Line Items]
Common stock, shares authorized		200,000,000
Common stock, par value		$ 0.0001
Preferred stock, authorized		10,000,000
Preferred stock, par value		$ 0.0001
Share price		$ 20.00
Proceeds from sale of common stock		$ 254,300

Investment Securities

12 Months Ended

Dec. 31, 2021

Investments Debt And Equity Securities [Abstract]

Investment Securities

5. Investment Securities

The Company’s investment policy defines allowable investment securities and establishes guidelines relating to credit quality, diversification, and maturities of its investments to preserve principal and maintain liquidity. In accordance with the Company’s investment policy, it has invested funds in marketable securities. The cost, gross unrealized holding gains, gross unrealized holding losses, allowances for credit losses and fair value of available-for-sale investments by types, maturities and classes of securities at December 31, 2021 and 2020 consisted of the following (in thousands):


		As of December 31, 2021
											Estimated
									Allowance		Fair
		Amortized		Unrealized		Unrealized			for Credit		Market
	Maturity	Cost		Gains		Losses			Losses		Value
Certificates of deposits	Within 1 year	$	2,896	$	—	$	(3	)	$	—	$	2,893
U.S. Treasury securities	Within 1 year		15,045		—		(23	)		—	$	15,022
Certificates of deposits	1 year to 2 years		2,887		—		(9	)		—		2,878
U.S. Treasury securities	1 year to 2 years		64,911		—		(209	)		—		64,702
Total		$	85,739	$	—	$	(244	)	$	—	$	85,495

		As of December 31, 2020
											Estimated
									Allowance		Fair
		Amortized		Unrealized		Unrealized			for Credit		Market
	Maturity	Cost		Gains		Losses			Losses		Value
Certificates of deposits	Within 1 year	$	1,750	$	4	$	—		$	—	$	1,754
U.S. Treasury securities	Within 1 year		31,806		152		—			—		31,958
Total		$	33,556	$	156	$	—		$	—	$	33,712

The Company reviews its investments at each reporting date to identify and evaluate whether a decline in fair value below the amortized cost basis of available-for-sale securities is due to credit-related factors and determines if such unrealized losses are the result of credit losses that require impairment. Factors considered in determining whether an unrealized loss is the result of a credit loss or other factors include the extent to which the fair value is less than the cost basis, any changes to the rating of the security by a rating agency, the financial condition and near-term prospects of the issuer, any historical failure of the issuer to make scheduled interest or principal payments, any adverse legal or regulatory events affecting the issuer or issuer’s industry, any significant deterioration in economic condition and the Company’s intent and ability to hold the investment for a period of time sufficient to allow for any anticipated recovery in market value.

At December 31, 2021 there were 38 securities in an unrealized loss position, all of which had been in an unrealized loss position for less than 12 months. The Company evaluated the securities individually for other-than-temporary impairment and considered the decline in market value to be primarily attributable to changes in interest rates. Each security remained at a high credit quality rating and the unrealized losses of each security was immaterial. Further, there had been no adverse conditions noted for any of the issuers and Company does not intend to sell any of the securities prior to maturity. As such, the Company has classified the losses as temporary in nature and the Company did not record a reserve for credit losses. At December 31, 2020, there were no securities in an unrealized loss position.

As of December 31, 2021, the Company held 24 domestic certificates of deposit with amortized costs below the Federal Deposit Insurance Corporation (“FDIC”) insured limit. Accrued interest receivable on available-for-sale investment securities, included in prepaids and other current assets on the Company’s balance sheets, was $0.1 million and less than $0.1 million at December 31, 2021 and 2020, respectively.

Grant Revenue

12 Months Ended

Dec. 31, 2021

Disaggregation Of Revenue [Abstract]

Grant Revenue

8. Grant Revenue

The Company recognizes revenue pursuant to grants, as described further in Note 2, by measuring the progress of the applicable research and development services provided over time, based on the effort the Company expends and costs incurred, relative to the estimated total effort and costs to be incurred under the grant. This results in a percentage that the Company multiplies by the grant award amount to determine the amount of grant revenue to be recognized each period. This approach requires the Company to use judgement and make estimates of future expenditures. If the Company’s estimates or judgements change over the course of the term of the grant, it may affect the timing and amount of revenue that it recognizes in the current and future periods.

During the year ended December 31, 2020, the Company recognized $0.2 million of grant revenue from awards by the NSF, NIH and FARA, respectively. No grant revenue was recognized for the year ended December 31, 2021.

Investment Securities (Tables)

12 Months Ended

Dec. 31, 2021

Investments Debt And Equity Securities [Abstract]

Disclosure - Investment Securities - Summary of Cost, Gross Unrealized Holding Gains and Losses, Allowances for Credit Losses and Fair Value of Available-for-Sale Investments by Types, Maturities and Classes of Securities (Detail)

The cost, gross unrealized holding gains, gross unrealized holding losses, allowances for credit losses and fair value of available-for-sale investments by types, maturities and classes of securities at December 31, 2021 and 2020 consisted of the following (in thousands):


		As of December 31, 2021
											Estimated
									Allowance		Fair
		Amortized		Unrealized		Unrealized			for Credit		Market
	Maturity	Cost		Gains		Losses			Losses		Value
Certificates of deposits	Within 1 year	$	2,896	$	—	$	(3	)	$	—	$	2,893
U.S. Treasury securities	Within 1 year		15,045		—		(23	)		—	$	15,022
Certificates of deposits	1 year to 2 years		2,887		—		(9	)		—		2,878
U.S. Treasury securities	1 year to 2 years		64,911		—		(209	)		—		64,702
Total		$	85,739	$	—	$	(244	)	$	—	$	85,495

		As of December 31, 2020
											Estimated
									Allowance		Fair
		Amortized		Unrealized		Unrealized			for Credit		Market
	Maturity	Cost		Gains		Losses			Losses		Value
Certificates of deposits	Within 1 year	$	1,750	$	4	$	—		$	—	$	1,754
U.S. Treasury securities	Within 1 year		31,806		152		—			—		31,958
Total		$	33,556	$	156	$	—		$	—	$	33,712

Net Loss Per Share

12 Months Ended

Dec. 31, 2021

Earnings Per Share [Abstract]

Net Loss Per Share

3. Net Loss Per Share

Basic net loss per share is computed by dividing the net loss by the weighted-average number of common shares outstanding during the period, without consideration for potentially dilutive securities. Diluted net loss per share is computed by dividing the net loss by the weighted average number of common shares and dilutive common stock equivalents outstanding for the period determined using the treasury-stock and if-converted methods. Dilutive common stock equivalents are comprised of convertible preferred stock, restricted common stock subject to repurchase, stock options outstanding under the Company’s equity incentive plans, employee stock purchase rights under the Company’s ESPP, and shares of common stock that are issuable under convertible debt, as applicable. For all periods presented, there is no difference in the number of shares used to calculate basic and diluted shares outstanding due to the Company's net loss position.


	December 31, 2021		December 31, 2020
Convertible preferred stock	$	—	$	13,504,598
Stock options		2,673,775		1,601,214
Shares subject to repurchase		239,826		646,953
Employee stock purchase plan		3,833		—
Total	$	2,917,434	$	15,752,765

Fair Value Measurements

12 Months Ended

Dec. 31, 2021

Fair Value Disclosures [Abstract]

Fair Value Measurements

4. Fair Value Measurements

Accounting guidance defines fair value, establishes a consistent framework for measuring fair value and expands disclosure for each major asset and liability category measured at fair value on either a recurring or non-recurring basis. Fair value is defined as an exit price, representing the amount that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants. As such, fair value is a market-based measurement that should be determined based on assumptions that market participants would use in pricing an asset or liability. As a basis for considering such assumptions, the accounting guidance establishes a three-tier fair value hierarchy, which prioritizes the inputs used in measuring fair value as follows:

Level 1: Observable inputs such as quoted prices in active markets.

Level 2: Inputs, other than the quoted prices in active markets that are observable either directly or indirectly.

Level 3: Unobservable inputs in which there is little or no market data, which require the reporting entity to develop its own assumptions.

The carrying value of the Company’s cash, accounts payable and accrued liabilities are considered to be representative of their respective fair values due to the short-term nature of those instruments. The Company’s investment securities, which may include money market accounts, money market funds, certificates of deposits, U.S. Treasury securities, and high quality, marketable debt instruments of corporations and government sponsored enterprises, are measured at fair value in accordance with the fair value hierarchy. None of the Company’s non-financial assets or liabilities are recorded at fair value on a non-recurring basis and no transfers between levels have occurred during the periods presented.

The following table summarizes the Company’s financial instruments measured at fair value on a recurring basis at December 31, 2021 and 2020 (in thousands):


	Fair Value Measurement at End of Period Using:
			Quoted Prices
			In Active
			Markets		Significant
			For		Other		Significant
			Identical		Observable		Unobservable
			Assets		Inputs		Inputs
	Total		(Level 1)		(Level 2)		(Level 3)
As of December 31, 2021:
Assets:
Money market funds(1)	$	298,114	$	298,114	$	—	$	—
Certificates of deposit		5,771		5,771		—		—
U.S. Treasury securities		79,724		79,724		—		—
Total	$	383,609	$	383,609	$	—	$	—
As of December 31, 2020:
Assets:
Money market funds(1)	$	2,100	$	2,100	$	—	$	—
Certificates of deposit		1,754		1,754		—		—
U.S. Treasury securities		31,958		31,958		—		—
Total	$	35,812	$	35,812	$	—	$	—

(1)

Included in cash and cash equivalents on the accompanying balance sheets.

Interest bearing money market accounts and certificates of deposit are valued at amortized cost, which approximates fair value.

- Definition

The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.

+ References + Details

Balance Sheets - USD ($) $ in Thousands	Dec. 31, 2021	Dec. 31, 2020
Current assets:
Cash and cash equivalents	$ 298,569	$ 2,379
Investment securities	85,495	33,712
Prepaid expenses and other current assets	1,371	142
Total current assets	385,435	36,233
Property and equipment, net	1,508	71
Right-of-use asset, related party	3,614
Deferred offering costs		212
Total assets	390,557	36,516
Current liabilities:
Accounts payable (including related party amounts of $0 and $20,respectively)	1,620	1,399
Accrued expenses and other current liabilities (including related party amounts of $504 and $0, respectively)	3,663	931
Total current liabilities	5,283	2,330
Operating lease liability, net, related party	3,144
Other long-term liabilities		145
Total liabilities	8,427	2,475
Commitments and contingencies (See Note 12)
Convertible preferred stock; $0.0001 par value; no shares and 22,012,499 shares issued and outstanding at December 31, 2021 and 2020,respectively; liquidation preference of zero and $45,625 as of December 31, 2021 and 2020, respectively		45,356
Stockholders’ equity (deficit):
Common stock: $0.0001 par value; 200,000,000 and 60,000,000 shares authorized, 55,681,752 and 16,604,774 shares issued, 55,441,926 and 15,957,821 shares outstanding at December 31, 2021 and 2020,respectively	6	1
Additional paid-in capital	429,824	451
Accumulated deficit	(47,456)	(11,923)
Accumulated other comprehensive income	(244)	156
Total stockholders’ equity (deficit)	382,130	(11,315)
Total liabilities, convertible preferred stock and stockholders’ equity (deficit)	$ 390,557	$ 36,516

Stock-Based Compensation - Summary of Stock Option Activity (Details) - USD ($) $ / shares in Units, $ in Thousands	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of Options and Awards Outstanding, Beginning Balance	1,601,214	30,674
Number of Options and Awards Outstanding, Granted	1,439,444	1,723,913
Number of Options and Awards Outstanding, Exercised	(52,974)	(153,373)
Number of Options and Awards Outstanding, Canceled	(313,909)
Number of Options and Awards Outstanding, Ending Balance	2,673,775	1,601,214	30,674
Number of Options and Awards Outstanding, Vested and expected to vest at December 31, 2021	2,673,775
Number of Options and Awards Outstanding, Exercisable at December 31, 2021	949,102
Weighted Average Exercise Price, Beginning Balance	$ 0.91	$ 0.003
Weighted Average Exercise Price, Granted	15.60	0.93
Weighted Average Exercise Price, Exercised	0.65	0.95
Weighted Average Exercise Price, Cancelled	3.82
Weighted Average Exercise Price, Ending Balance	8.49	$ 0.91	$ 0.003
Weighted Average Exercise Price, Vested and expected to vest at December 31, 2021	8.49
Weighted Average Exercise Price, Exercisable at December 31, 2021	$ 2.34
Weighted Average Remaining Contractual Term (Years)	9 years 1 month 13 days	9 years 8 months 15 days	9 years 11 months 12 days
Weighted Average Remaining Contractual Term (Years), Vested and expected to vest at December 31, 2021	9 years 1 month 13 days
Weighted Average Remaining Contractual Term (Years), Exercisable at December 31, 2021	8 years 9 months 10 days
Aggregate Intrinsic Value	$ 35,343	$ 8,468
Aggregate Intrinsic Value, Vested and expected to vest at December 31, 2021	35,343
Aggregate Intrinsic Value, Exercisable at December 31, 2021	$ 18,159

Stock-Based Compensation - Stock-Based Compensation Expense for Equity Awards Reported in Statements of Operations and Comprehensive Loss (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock-based compensation expense	$ 4,689	$ 450
Research and Development
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock-based compensation expense	1,827	177
General and Administrative
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock-based compensation expense	$ 2,862	$ 273

Related Party Transactions - Summary of Expenses Recognized under Consulting Agreement (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
Related Party Transaction [Line Items]
Research and development	$ 24,778	$ 6,060
General and administrative	11,053	2,496
Lease Agreement
Related Party Transaction [Line Items]
Research and development	225
General and administrative	88
Total expenses	313
Research Consulting Agreements
Related Party Transaction [Line Items]
Research and development	180	45
Total expenses	180	45
Marlinspike Group, LLC \| Consulting Agreements
Related Party Transaction [Line Items]
Research and development		8
General and administrative	240	292
Total expenses	$ 240	$ 300

Balance Sheets (Parenthetical) - USD ($) $ in Thousands	Dec. 31, 2021	Dec. 31, 2020
Statement Of Financial Position [Abstract]
Accounts payable, related party amounts	$ 0	$ 20
Accrued expenses and other current liabilities, related party amounts	$ 504	$ 0
Convertible preferred stock, par value	$ 0.0001	$ 0.0001
Convertible preferred stock, issued	0	22,012,499
Convertible preferred stock, outstanding	0	22,012,499
Convertible preferred stock, liquidation preference	$ 0	$ 45,625
Common stock, par value	$ 0.0001	$ 0.0001
Common stock, shares authorized	200,000,000	60,000,000
Common stock, shares issued	55,681,752	16,604,774
Common stock, shares outstanding	55,441,926	15,957,821

Statements of Operations - USD ($) $ in Thousands	12 Months Ended
Statements of Operations - USD ($) $ in Thousands	Dec. 31, 2021	Dec. 31, 2020
Revenue:
Grant revenue		$ 226
Revenue, Product and Service [Extensible List]	us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned	us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned
Operating expenses:
Research and development (including related party amounts of $405 and $53, respectively)	$ 24,778	$ 6,060
General and administrative (including related party amounts of $328 and $292, respectively)	11,053	2,496
Total operating expenses	35,831	8,556
Loss from operations	(35,831)	(8,330)
Other income, net (including related party expense amounts of $0 and $30, respectively)	298	50
Net loss	$ (35,533)	$ (8,280)
Net loss per share, basic and diluted	$ (0.77)	$ (0.52)
Weighted-average shares of common stock outstanding, basic and diluted	45,936,235	15,796,674

Commitments and Contingencies

12 Months Ended

Dec. 31, 2021

Commitments And Contingencies Disclosure [Abstract]

Commitments and Contingencies

12. Commitments and Contingencies

Notes Payable-Related Party

In January 2019, the Company issued an unsecured promissory note to borrow up to $0.5 million to a co-founder (the “January Note”) for working capital. The January Note bore interest at prime plus 4.5%, was scheduled to mature on or before January 30, 2021 and included a final payment of 3% on the amounts advanced at maturity. In February and March 2019, the Company borrowed an aggregate of $0.2 million under the January Note with interest payable at 10% per annum. The Company recorded an immaterial amount of debt issuance costs associated with the January Note. The debt issuance costs and final payment for the advances were amortized to interest expense using the effective interest rate method over the loan term. The principal and interest payable on the January Note were repaid in full in 2020.1

In November 2019, the Company issued an unsecured promissory note to borrow up to $0.5 million to a co-founder (the “November Note”) for working capital. The November Note bore interest at prime plus 4.5% and matured on or before January 1, 2022 and included a final payment of 3% on the amounts advanced at maturity. In December 2019 and January 2020, the Company borrowed a total of $0.4 million under the November Note with interest payable at 9.25% per annum. The final payment on the advances was amortized to interest expense using the effective interest rate method over the loan term. The principal and interest payable on the November Note were repaid in full in 2020.

Convertible Notes

In May and July 2018, the Company issued $0.3 million of convertible notes to a co-founder for cash with a maturity date on or after February 5, 2021, if not converted earlier. In February 2019, the Company issued an additional $0.2 million of convertible notes to consultants for services rendered with a maturity date on or after May 16, 2020, if not converted earlier. The convertible notes bore interest of 8% per annum and were convertible into equity securities sold at the next financing at 80% of the selling price per share of such equity financing. The conversion features of the convertible notes were recorded as a discount to the notes payable at issuance and amortized as interest expense over the loan term using the effective interest rate method.

In February 2020, the outstanding principal and accrued interest of the convertible notes totaling $0.5 million were converted into 301,685 shares of the Company’s Series A convertible preferred stock at $1.65816 per share. See Note 9 for further discussion.

Contingencies

From time to time, the Company may become subject to claims or suits arising in the ordinary course of business. The Company accrues a liability for such matters when it is probable that the future expenditures will be made and such expenditures can be reasonably estimated. The Company had no such contingent liabilities as of December 31, 2021 or December 31, 2020.

Balance Sheet Details - Summary of Property and Equipment (Details) - USD ($) $ in Thousands	Dec. 31, 2021	Dec. 31, 2020
Property Plant And Equipment [Line Items]
Property and equipment	$ 1,642	$ 76
Less accumulated depreciation	(134)	(5)
Total	1,508	71
Laboratory Equipment
Property Plant And Equipment [Line Items]
Property and equipment	1,148	$ 76
Computer Equipment and Software
Property Plant And Equipment [Line Items]
Property and equipment	96
Furniture and Fixtures
Property Plant And Equipment [Line Items]
Property and equipment	292
Leasehold Improvements
Property Plant And Equipment [Line Items]
Property and equipment	95
Construction in Progress
Property Plant And Equipment [Line Items]
Property and equipment	$ 11

Convertible Preferred Stock and Stockholders' Deficit

12 Months Ended

Dec. 31, 2021

Equity [Abstract]

Convertible Preferred Stock and Stockholders' Deficit

9. Convertible Preferred Stock and Stockholders’ Deficit

Authorized Shares

In connection with the completion of the Company’s initial public offering (“IPO”) in March 2021, the Company amended its Certificate of Incorporation to authorize 200,000,000 shares of common stock, par value $0.0001 per share, and 10,000,000 shares of preferred stock, par value $0.0001 per share, respectively.

Convertible Preferred Stock

In February and March 2020, the Company issued 21,710,814 shares of Series A convertible preferred stock at $2.0727 per share for net cash proceeds of $ 44.7 million (the “Series A Financing”). In connection with the Series A Financing, the Company issued an additional 301,685 shares of its Series A convertible preferred stock at $1.65816 per share in February 2020 upon the conversion and extinguishment of its convertible notes, as discussed further in Note 8.

In January 2021, the Company issued 19,083,979 shares of Series B convertible preferred stock at $6.55 per share for net cash proceeds of approximately $124.7 million.

All shares of convertible preferred stock outstanding at the Company’s IPO were converted into shares of the Company’s common stock.

Shares Subject to Repurchase

Pursuant to the 2018 Plan, the Company has issued shares of restricted common stock to employees, consultants and members of its board of directors. Additionally, certain stock options granted pursuant to the 2018 Plan provide for the right to elect to exercise unvested options early in exchange for restricted shares of common stock. These restricted shares of common stock generally vest over a four-year period and are subject to repurchase by the Company at the original purchase price or, in certain instances the fair market value if such fair market value is lower than the purchase price, in the event the recipient’s service is terminated either voluntarily or involuntarily prior to vesting.


	Shares			Liability
Balance at December 31, 2019		811,268		$	1
Shares early exercised		153,373			145
Vested shares		(317,688	)		(1	)
Balance at December 31, 2020		646,953			145
Vested shares		(407,127	)		(122	)
Balance at December 31, 2021		239,826		$	23

- Definition

The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 13
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 13
-URI http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 14
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=123467817&loc=SL123496171-112644

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 14
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=123467817&loc=SL123496171-112644

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.3-04)
-URI http://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 18
-Subparagraph (d)
-URI http://asc.fasb.org/extlink&oid=123467817&loc=SL123496189-112644

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 13
-Subparagraph (g)
-URI http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644

Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-URI http://asc.fasb.org/topic&trid=2208762

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 18
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=123467817&loc=SL123496189-112644

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 13
-Subparagraph (h)
-URI http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 14
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=123467817&loc=SL123496171-112644

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 18
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=123467817&loc=SL123496189-112644

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 16
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=123467817&loc=SL123496180-112644

Reference 14: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 13
-Subparagraph (i)
-URI http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644

Reference 15: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(e)(1))
-URI http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690

+ Details

Income Taxes (Tables)

12 Months Ended

Dec. 31, 2021

Income Tax Disclosure [Abstract]

Significant Components of Net Deferred Tax Assets

Significant components of the Company's net deferred tax assets at December 31, 2021 and 2020 were as follows (in thousands):


	December 31, 2021			December 31, 2020
Deferred tax assets:
Net operating losses	$	9,171		$	2,836
Research and development credits		1,013			153
Lease liability		763			—
Stock-based compensation		532			25
Other		515			196
Total gross deferred tax assets		11,994			3,210
Valuation allowance		(11,235	)		(3,177	)
Total deferred tax assets		759			33
Deferred tax liabilities:
Right of use asset		(759	)		—
Other		—			(33	)
Total deferred tax liabilities		(759	)		(33	)
Net deferred tax assets	$	—		$	—

Schedule of Reconciliation of Income Tax Expense (Benefit)

A reconciliation of the Company's income tax expense (benefit) to the amount computed by applying the federal statutory income tax rate for the periods presented were as follows (in thousands):


	December 31, 2021			December 31, 2020
Expected tax benefit at federal statutory rate	$	(7,451	)	$	(1,738	)
State income taxes, net of federal benefit		(4	)		(552	)
Debt financing		—			6
Research and development credits		(836	)		(71	)
Other		317			174
Change in valuation allowance		7,974			2,181
Provision for income taxes	$	—		$	—

Summary of Changes to Unrecognized Tax Benefits

The following table summarizes the changes to the Company's unrecognized tax benefits for the periods presented (in thousands):


	December 31, 2021		December 31, 2020
Balance at beginning of period	$	15	$	9
Increase related to prior year tax positions		1		—
Increase to current year tax positions		402		6
Balance at end of period	$	418	$	15

Investment Securities - Summary of Cost, Gross Unrealized Holding Gains and Losses, Allowances for Credit Losses and Fair Value of Available-for-Sale Investments by Types, Maturities and Classes of Securities (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
Schedule Of Available For Sale Securities [Line Items]
Debt securities, Amortized Cost	$ 85,739	$ 33,556
Debt securities, Unrealized Gains		156
Debt securities, Unrealized Losses	(244)
Debt securities, Estimated Fair Value	$ 85,495	$ 33,712
Certificates of deposit \| Within 1 Year
Schedule Of Available For Sale Securities [Line Items]
Debt securities, Maturity	Within 1 year	Within 1 year
Debt securities, Amortized Cost	$ 2,896	$ 1,750
Debt securities, Unrealized Gains		4
Debt securities, Unrealized Losses	(3)
Debt securities, Estimated Fair Value	$ 2,893	$ 1,754
Certificates of deposit \| 1 Year to 2 Years
Schedule Of Available For Sale Securities [Line Items]
Debt securities, Maturity	1 year to 2 years
Debt securities, Amortized Cost	$ 2,887
Debt securities, Unrealized Losses	(9)
Debt securities, Estimated Fair Value	$ 2,878
U.S. Treasury securities \| Within 1 Year
Schedule Of Available For Sale Securities [Line Items]
Debt securities, Maturity	Within 1 year	Within 1 year
Debt securities, Amortized Cost	$ 15,045	$ 31,806
Debt securities, Unrealized Gains		152
Debt securities, Unrealized Losses	(23)
Debt securities, Estimated Fair Value	$ 15,022	$ 31,958
U.S. Treasury securities \| 1 Year to 2 Years
Schedule Of Available For Sale Securities [Line Items]
Debt securities, Maturity	1 year to 2 years
Debt securities, Amortized Cost	$ 64,911
Debt securities, Unrealized Losses	(209)
Debt securities, Estimated Fair Value	$ 64,702

Balance Sheet Details - Summary of Accrued Liabilities (Details) - USD ($) $ in Thousands	Dec. 31, 2021	Dec. 31, 2020
Accrued Liabilities Current [Abstract]
Accrued personnel costs	$ 2,152	$ 565
Accrued research and development costs	516	266
Current portion of operating lease liability, related party	$ 489
Operating Lease, Liability, Current, Statement of Financial Position [Extensible Enumeration]	Operating Lease, Right-of-Use Asset
Accrued other	$ 506	100
Total	$ 3,663	$ 931

License Agreement - Additional Information (Details) - License Agreement - USD ($)	1 Months Ended		12 Months Ended
	Feb. 29, 2020	Feb. 28, 2019	Dec. 31, 2021	Dec. 31, 2020
Schedule Of License Agreement [Line Items]
Upfront payment upon execution of agreement		$ 25,000
Upfront payment within first anniversary of license agreement		225,000
Written notice period for termination of agreement			90 days
Termination period Description			WARF may terminate the License Agreement with 90 days written notice if first commercial sale does not occur before December 31, 2031. Unless terminated earlier by the parties, the term of the License Agreement will continue until the last licensed patent expires in all countries.
Investigation New Drug (IND)
Schedule Of License Agreement [Line Items]
Expected milestone payment on achieving certain regulatory and commercial milestones			$ 125,000
Milestone payment			0
Royalty payments			0
Investigation New Drug (IND) \| Maximum
Schedule Of License Agreement [Line Items]
Expected milestone payment on achieving certain regulatory and commercial milestones			17,500,000
Investigation New Drug (IND) \| Minimum [Member]
Schedule Of License Agreement [Line Items]
Expected royalty payments upon first commercial product sale			100,000
Initial Closing of Series A Preferred Stock
Schedule Of License Agreement [Line Items]
Payment for upfront fee	$ 225,000
Research and Development
Schedule Of License Agreement [Line Items]
Payment for upfront fee		$ 250,000
General and Administrative Expenses
Schedule Of License Agreement [Line Items]
Legal patent fees			$ 100,000
General and Administrative Expenses \| Maximum
Schedule Of License Agreement [Line Items]
Legal patent fees				$ 100,000

Stock-Based Compensation

12 Months Ended

Dec. 31, 2021

Share-based Payment Arrangement [Abstract]

Stock-Based Compensation

10. Stock-Based Compensation

Equity Incentive Award Plans

In March 2021, the Company’s board of directors and stockholders adopted the 2021 Plan, which became effective on March 25, 2021, the date of the underwriting agreement related to the Company’s IPO. Upon adoption of the 2021 Plan, the Company restricted future grants from its 2018 Plan.

Under the 2021 Plan, the Company may grant stock options, stock appreciation rights, restricted stock, restricted stock units, performance stock awards, performance cash awards and other forms of stock awards to employees, directors and consultants, including employees and consultants of the Company’s affiliates. A total of 6,118,648 new shares of common stock were approved to be initially reserved for issuance under the 2021 Plan. The number of shares reserved under the 2021 Plan also include 881,352 shares of common stock that remained available for issuance under the 2018 Plan at the time the 2021 Plan became effective, and will be increased by the number of shares under the 2018 Plan that are repurchased, forfeited, expired or cancelled on or after the effective date of the 2021 Plan. As of December 31, 2021, the Company had 6,079,984 shares available for grant under the 2021 Plan. In addition, the number of shares of common stock available for issuance under the 2021 Plan will automatically increase on January 1 of each calendar year, starting on January 1, 2022 through January 1, 2031, in an amount equal to 5% of the total number of shares outstanding of the Company’s common stock on the last day of the calendar month before the date of each automatic increase, or a lesser number of shares determined by the Company’s board of directors. Effective January 1, 2022, the number of shares available for future issuance was increased by 2,784,087 shares so that the total available for future issuance as of January 1, 2022 was 8,864,071 shares.

A summary of the Company's stock option activity for the periods presented was as follows (in thousands, except year, share and per share data):


						Weighted-
						Average
	Number of			Weighted-		Remaining
	Options and			Average		Contractual		Aggregate
	Awards			Exercise		Term		Intrinsic
	Outstanding			Price		(Years)		Value
Outstanding at December 31, 2019		30,674		$	0.003		9.95	$	—
Granted		1,723,913		$	0.93
Exercised		(153,373	)	$	0.95
Canceled		—		$	—
Outstanding at December 31, 2020		1,601,214		$	0.91		9.71		8,468
Granted		1,439,444		$	15.60
Exercised		(52,974	)	$	0.65
Canceled		(313,909	)	$	3.82
Outstanding at December 31, 2021		2,673,775		$	8.49		9.12	$	35,343
Vested and expected to vest at December 31, 2021		2,673,775		$	8.49		9.12	$	35,343
Exercisable at December 31, 2021		949,102		$	2.34		8.78	$	18,159

The weighted-average grant date fair value per share of options granted was $12.39 and $4.49 for the years ended December 31, 2021 and 2020, respectively. The aggregate intrinsic value of options exercised was $0.8 million and zero for the years ended December 31, 2021 and 2020, respectively, and the cash received from options exercised was less than $0.1 million and $0.1 million for the years ended December 31, 2021 and 2020.

The weighted-average assumptions used in the Black-Scholes option pricing model to determine the fair value of stock option grants for the periods presented were as follows:


	Year Ended December 31,
	2021			2020
Fair value of common stock		15.60			5.08
Expected term (years)		6.07			6.32
Expected volatility		72.83	%		72.93	%
Risk-free interest rate		1.04	%		0.62	%
Expected dividend yield		0.0	%		0.0	%

The Company determines the assumptions used in the option pricing model in the following manner:

Fair Value of Common Stock—The grant date fair market value of the shares of common stock underlying stock options is determined by the Company’s board of directors. Following the closing of the Company’s IPO, the fair market value of our common stock is based on its closing price as reported on the date of grant on the primary stock exchange on which the Company’s common stock is traded. Prior to the Company’s IPO, because there was no public market for the Company’s common stock, the board of directors considered, among other things, input from management and valuations of the Company's stock prepared by unrelated third-party valuation firms.

Expected Term—The expected term of stock options represents the period of time that the awards are expected to be outstanding. Because the Company does not have sufficient historical exercise behavior, it determines the expected term assumption using the simplified method for employees and board members, which calculates the expected term as the average time-to-vesting and the contractual life of the award. The expected term for non-employees is generally the contractual term.

Expected Volatility—Given the Company's limited historical stock price volatility data, the expected volatility assumption was determined by examining the historical volatilities of a group of industry peers whose share prices are publicly available.

Risk-Free Interest Rate—The risk-free rate assumption is based on the U.S. Treasury yield in effect at the time of the grant with maturities consistent with the expected term of the awards.

Expected Dividend Yield—The expected dividend yield assumption is based on the Company’s history and expectation of dividend payouts. The Company has not paid and does not intend to pay dividends and, therefore, used an expected dividend yield of zero.

2021 Employee Stock Purchase Plan

In March 2021, the Company’s board of directors and stockholders adopted the 2021 Employee Stock Purchase Plan (the “ESPP”), which became effective on March 25, 2021, the date of the underwriting agreement related to the Company’s IPO. The ESPP permits eligible employees who elect to participate in an offering under the ESPP to have up to 15% of their eligible earnings withheld, subject to certain limitations, to purchase shares of common stock pursuant to the ESPP. The price of common stock purchased under the ESPP is equal to 85% of the lower of the fair market value of the common stock at the commencement date of each offering period or the relevant date of purchase.

A total of 600,000 shares of common stock were approved to be initially reserved for issuance under the ESPP. In addition, the number of shares of common stock available for issuance under the ESPP will automatically increase on January 1 of each calendar year, starting on January 1, 2022 through January 1, 2031, in an amount equal to the lesser of (i) 1% of the total number of shares outstanding of the Company’s common stock on the last day of the calendar month before the date of each automatic increase and (ii) 1,200,000 shares; provided that before the date of any such increase, the Company’s board of directors may determine that such increase will be less than the amount set forth in clauses (i) and (ii). Effective January 1, 2022, the number of shares available for issuance was increased by 556,817 shares so that the total available for future issuance as of January 1, 2022 was 1,145,361 shares.

As of December 31, 2021, the Company had issued 11,456 shares of the Company's common stock under the ESPP and had 588,544 shares available for future issuance.

In determining the grant date fair value of shares to be issued under the ESPP, the Company uses the Black-Scholes option pricing model. The Black-Scholes inputs are determined in the same manner as for stock option awards. The weighted average inputs used for the ESPP for the year ended December 31, 2021, were as follows:


	Year Ended December 31,
	2021
Fair value of common stock		19.96
Expected term (years)		1.41
Expected volatility		69.26	%
Risk-free interest rate		0.18	%
Expected dividend yield		0.0	%

Stock-based compensation expense for all equity awards has been reported in the statements of operations and comprehensive loss as follows (in thousands):


	Year Ended December 31,
	2021		2020
Research and development	$	1,827	$	177
General and administrative		2,862		273
Total	$	4,689	$	450

As of December 31, 2021, unrecognized compensation expense related to unvested stock option awards was $18.0 million, which is expected to be recognized in expense over a weighted-average period of 3.2 years. As of December 31, 2021, unrecognized compensation expense related to ESPP rights was $0.4 million, which is expected to be recognized over a remaining period of 1.8 years.

Income Taxes - Schedule of Components of Net Deferred Tax Assets (Details) - USD ($) $ in Thousands	Dec. 31, 2021	Dec. 31, 2020
Deferred tax assets:
Net operating losses	$ 9,171	$ 2,836
Research and development credits	1,013	153
Lease liability	763
Stock-based compensation	532	25
Other	515	196
Total gross deferred tax assets	11,994	3,210
Valuation allowance	(11,235)	(3,177)
Total deferred tax assets	759	33
Deferred tax liabilities:
Right of use asset	(759)
Other		(33)
Total deferred tax liabilities	$ (759)	$ (33)

Income Taxes

12 Months Ended

Dec. 31, 2021

Income Tax Disclosure [Abstract]

Income Taxes

11. Income Taxes

The Company is subject to taxation in the United States and various state jurisdictions. All of the Company’s tax years are subject to examination by federal and state tax authorities due to the carryforward of unutilized net operating losses and research and development credits. The Company’s policy is to recognize interest and penalties related to income tax matters as tax expense. The Company had no accrued interest or penalties related to income tax matters on its balance sheets at December 31, 2021 or 2020. and has not recognized interest or penalties in its statements of operations and comprehensive loss for the years ended December 31, 2021 and 2020, respectively. Further, the Company is not currently under examination by any federal, state or local tax authority.

At December 31, 2021, the Company had federal and state net operating loss (“NOL”) carryforwards of $40.3 million and $10.4 million, respectively. Federal NOL carryforwards totaling $0.1 million begin to expire in 2037, unless previously utilized, and federal NOL carryforwards of $40.2 million generated after 2017, may be carryforward indefinitely but can only be utilized to offset 80% of future taxable income. State NOL carryforwards totaling $10.4 million begin to expire in 2037, unless previously utilized. In addition, the Company also has federal and state research and development (“R&D”) credit carryforwards totaling $0.9 million and $0.6 million, respectively. The federal R&D credit carryforwards will begin to expire in 2038 unless previously utilized. The state R&D credit carryforwards do not expire.

Utilization of the Company’s NOL and R&D credit carryforwards may be subject to substantial annual limitations in the event a cumulative ownership change has occurred, or that could occur in the future, as required by Section 382 of the Internal Revenue Code of 1986, as amended (the “Code”). In general, an “ownership change,” as defined by Section 382 of the Code, results from a transaction, or series of transactions over a three-year period, resulting in an ownership change of more than 50% of the outstanding common stock of a company by certain stockholders or public groups. Such an ownership change may limit the amount of NOL and R&D credit carryforwards that can be utilized annually to offset future taxable income and tax, respectively. The Company completed a study to assess whether an ownership change had occurred from the Company's formation through December 31, 2021. Based upon the study, the Company determined that it had experienced multiple ownership

changes during 2020, causing the annual utilization of the NOL and credit carryforwards to be limited. The Company does not believe any of the NOL and credit carryforwards generated through December 31, 2021 would expire solely as a result of annual limitations on the utilization of those attributes. If ownership changes occur in the future, the amount of remaining tax attribute carryforwards available to offset taxable income and income tax expense in future years may be restricted or eliminated. If eliminated, the related asset would be removed from deferred tax assets with a corresponding reduction in the valuation allowance. Due to the existence of the valuation allowance, limitations created by future ownership changes, if any, will not impact the Company’s effective tax rate.

Significant components of the Company's net deferred tax assets at December 31, 2021 and 2020 were as follows (in thousands):


	December 31, 2021			December 31, 2020
Deferred tax assets:
Net operating losses	$	9,171		$	2,836
Research and development credits		1,013			153
Lease liability		763			—
Stock-based compensation		532			25
Other		515			196
Total gross deferred tax assets		11,994			3,210
Valuation allowance		(11,235	)		(3,177	)
Total deferred tax assets		759			33
Deferred tax liabilities:
Right of use asset		(759	)		—
Other		—			(33	)
Total deferred tax liabilities		(759	)		(33	)
Net deferred tax assets	$	—		$	—

A reconciliation of the Company's income tax expense (benefit) to the amount computed by applying the federal statutory income tax rate for the periods presented were as follows (in thousands):


	December 31, 2021			December 31, 2020
Expected tax benefit at federal statutory rate	$	(7,451	)	$	(1,738	)
State income taxes, net of federal benefit		(4	)		(552	)
Debt financing		—			6
Research and development credits		(836	)		(71	)
Other		317			174
Change in valuation allowance		7,974			2,181
Provision for income taxes	$	—		$	—

The Company recognizes a tax benefit from an uncertain tax position when it is more likely than not that the position will be sustained upon examination by tax authorities. The Company does not expect that there will be a significant change in the unrecognized tax benefits over the next twelve months. Further, due to the existence of the valuation allowance, future changes in the Company's unrecognized tax benefits will not impact the effective tax rate.

The following table summarizes the changes to the Company's unrecognized tax benefits for the periods presented (in thousands):


	December 31, 2021		December 31, 2020
Balance at beginning of period	$	15	$	9
Increase related to prior year tax positions		1		—
Increase to current year tax positions		402		6
Balance at end of period	$	418	$	15

- Definition

The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 21
-URI http://asc.fasb.org/extlink&oid=121826272&loc=d3e32857-109319

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SAB Topic 11.C)
-URI http://asc.fasb.org/extlink&oid=122134291&loc=d3e330215-122817

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 17
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=121826272&loc=d3e32809-109319

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SAB TOPIC 6.I.5.Q1)
-URI http://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 14
-URI http://asc.fasb.org/extlink&oid=121826272&loc=d3e32705-109319

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 270
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6424409&loc=d3e44925-109338

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-URI http://asc.fasb.org/topic&trid=2144680

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 30
-Section 50
-Paragraph 2
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=6424122&loc=d3e41874-109331

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(h)(2))
-URI http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690

+ Details

Lease - Summary of Maturities of Operating Lease Liabilities, Related Party (Details) $ in Thousands	Dec. 31, 2021 USD ($)
Operating Lease Liabilities Payments Due [Abstract]
2022	$ 733
2023	755
2024	778
2025	801
2026	825
Thereafter	561
Total future minimum lease payments	4,453
Less: Present value adjustment	(820)
Operating lease liabilities, related party	$ 3,633

Balance Sheet Details

12 Months Ended

Dec. 31, 2021

Balance Sheet Component [Abstract]

Balance Sheet Details

6. Balance Sheet Details

Prepaid expenses and other current assets consisted of the following (in thousands):


	December 31, 2021		December 31, 2020
Prepaid expenses	$	1,254	$	60
Security deposits		—		47
Interest receivable		110		10
Other		7		25
Total	$	1,371	$	142

Property and equipment consisted of the following (in thousands):


	December 31, 2021			December 31, 2020
Laboratory equipment	$	1,148		$	76
Computer equipment and software		96			—
Furniture and fixtures		292			—
Leasehold improvements		95			—
Construction in progress		11			—
		1,642			76
Less accumulated depreciation		(134	)		(5	)
Total	$	1,508		$	71

Accrued liabilities consisted of the following (in thousands):


	December 31, 2021		December 31, 2020
Accrued personnel costs	$	2,152	$	565
Accrued research and development costs		516		266
Current portion of operating lease liability, related party		489		—
Accrued other		506		100
Total	$	3,663	$	931

Balance Sheet Details - Summary of Prepaid Expenses and Other Current Assets (Details) - USD ($) $ in Thousands	Dec. 31, 2021	Dec. 31, 2020
Prepaid Expense And Other Assets Current [Abstract]
Prepaid expenses	$ 1,254	$ 60
Security deposits		47
Interest receivable	110	10
Other	7	25
Total	$ 1,371	$ 142

Lease (Tables)

12 Months Ended

Dec. 31, 2021

Leases [Abstract]

Summary of Maturities of Operating Lease Liabilities, Related Party

Maturities of operating lease liabilities, related party as of December 31, 2021 are as follows (in thousands):


2022	$	733
2023		755
2024		778
2025		801
2026		825
Thereafter		561
Total future minimum lease payments		4,453
Less: Present value adjustment		(820	)
Operating lease liabilities, related party	$	3,633

Employee Benefit Plans - Additional Information (Details)	12 Months Ended
	Dec. 31, 2021 USD ($)
Retirement Benefits [Abstract]
Contributions made under plan	$ 0

Summary of Significant Accounting Policies - Additional Information (Details) - USD ($)	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
Property Plant And Equipment [Line Items]
Short-term leases	$ 0	$ 0
Impairment losses	$ 0	$ 0
Maximum [Member]
Property Plant And Equipment [Line Items]
Property and equipment, estimated useful lives	5 years
Minimum [Member]
Property Plant And Equipment [Line Items]
Property and equipment, estimated useful lives	3 years

Summary of Significant Accounting Policies

12 Months Ended

Dec. 31, 2021

Accounting Policies [Abstract]

Summary of Significant Accounting Policies

2. Summary of Significant Accounting Policies

Basis of Presentation and Use of Estimates

The financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (GAAP). The preparation of financial statements in conformity with GAAP requires the Company to make estimates and assumptions that affect the reported amounts of assets and liabilities and

disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of product sales and expense during the reporting period. Although these estimates are based on the Company’s knowledge of current events and anticipated actions it may undertake in the future, actual results may ultimately materially differ from these estimates and assumptions.

The preparation of the Company’s financial statements requires it to make estimates and assumptions that impact the reported amounts of assets, liabilities, revenues and expenses and the disclosure of contingent assets and liabilities in the Company’s financial statements and accompanying notes. The most significant estimates in the Company’s financial statements relate to the recognition of grant revenue, accruals for research and development expenses and the valuation of equity-based awards. These estimates and assumptions are based on current facts, historical experience and various other factors believed to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities and the recording of revenue and expenses that are not readily apparent from other sources. Actual results may differ materially and adversely from these estimates.

The full extent to which the novel coronavirus-2019 (“COVID-19”) pandemic will directly or indirectly impact the Company’s business, results of operations and financial condition, including research and development costs, will depend on future developments that are highly uncertain, including as a result of new information that may emerge concerning COVID-19 and the actions taken to contain or treat COVID-19, as well as the economic impact on local, regional, national and international markets. The Company has considered potential impacts arising from the COVID-19 pandemic and is not presently aware of any events or circumstances that would require the Company to update its estimates, judgments or revise the carrying value of its assets or liabilities.

Segment Reporting

Operating segments are identified as components of an enterprise about which separate discrete financial information is available for evaluation by the chief operating decision-maker in making decisions regarding resource allocation and assessing performance. The Company manages its operations as a single reportable segment for the purposes of assessing performance and making operating decisions.

Concentrations of Credit Risk

Financial instruments that potentially subject the Company to significant concentrations of credit risk consist primarily of cash, cash equivalents and investment securities. The Company maintains deposits in federally insured financial institutions in excess of federally insured limits. The Company has not experienced any losses in such accounts and believes it is not exposed to significant risk on its cash balances due to the financial position of the depository institution in which those deposits are held. Additionally, the Company has established guidelines regarding approved investments and maturities of investments, which are designed to maintain safety and liquidity.

Cash and Cash Equivalents

The Company considers all highly liquid investments with maturities at the date of acquisition of three months or less to be cash equivalents. These investments may include money market accounts, money market funds, U.S. Government agency securities, corporate debt securities and commercial paper. The carrying amounts approximate fair value due to the short maturities of these instruments. The Company’s cash reserves are in a readily available checking account.

Investment Securities

Investments in securities with maturities at the date of acquisition of more than three months are considered marketable securities. These investments may include money market accounts, money market funds, certificates of deposits, U.S. Treasury securities, and high quality, marketable debt instruments of corporations and government sponsored enterprises. The Company determines the appropriate classification of its investments at the time of acquisition and reevaluates such determination at each balance sheet date. The Company has classified its investment holdings as available-for-sale, as the sale of such securities may be required prior to maturity to implement management strategies. Further, the Company classifies its available-for-sale investment securities, including those with maturities beyond one year, as current assets on its balance sheets based on the highly liquid nature of the securities and because these investments are considered available for use in current operations. The Company’s investment policy sets minimum credit quality criteria and maximum maturity limits on its investments to provide for safety of principle, liquidity and a reasonable rate of return. Available-for-sale securities are recorded at fair value, based on current market valuations. Unrealized holding gains and losses on available-for-sale securities are excluded from earnings and are reported as a separate component of other comprehensive income (loss) until realized. Allowances for credit losses are reported on the balance sheet, if any.

The cost of available-for-sale investment securities is adjusted for amortization of premiums and accretion of discounts until the securities mature. Such amortization and accretion is included in other income, net on the statements of operations. Realized gains and losses, if any, are also included in other income, net on the statement of operations and are derived using the specific identification method for determining the cost of the securities sold. During the periods presented, no realized gains or losses were recorded on the sale of investment securities and no impairments to reduce the value of any security was taken. See Note 5 for further discussion.

Property and Equipment, Net

Property and equipment generally consist of laboratory equipment, computer equipment and software, and furniture and fixtures and are recorded at cost and depreciated using the straight-line method over the estimated useful lives of the assets (generally three to five years). Leasehold improvements are recorded at cost and are depreciated on a straight-line basis over the lesser of the remaining term of the related lease or the estimated useful lives of the assets. Repairs and maintenance costs are charged as incurred.

An impairment loss is recorded if and when events and circumstances indicate that assets might be impaired and the undiscounted cash flows estimated to be generated by those assets are less than the carrying amount of those assets. The Company has not recognized any impairment losses for the years ended December 31, 2021 and 2020.

Leases

Leases consist of an operating lease the Company has related to its facility. At lease commencement, the Company records a lease liability based on the present value of lease payments over the expected lease term. The expected lease term includes noncancelable lease periods and, when applicable, periods covered by an option to extend the lease if the Company is reasonably certain to exercise that option, as well as periods covered by an option to terminate the lease if the Company is reasonably certain not to exercise the option. For those leases where the implicit rate is not provided, the Company calculates the present value of lease payments using an incremental borrowing rate. The Company's incremental borrowing rate for a lease is the rate of interest it would have to pay on a collateralized basis to borrow an amount equal to the lease payments under similar terms. At the lease commencement date, the Company records a corresponding right-of-use ("ROU") lease asset based on the lease liability, adjusted for any lease incentives received and any initial direct costs paid to the lessor prior to the lease commencement date. The Company may enter into leases with an initial term of 12 months or less ("Short-Term Leases"). For any Short-Term leases, the Company records the rent expense on a straight-line basis and ROU asset and lease obligations are not recognized. The Company had no Short-Term Leases as of December 31, 2021 or 2020.

After lease commencement, the Company measures its leases as follows: (i) the lease liability based on the present value of the remaining lease payments using the discount rate determined at lease commencement and (ii) the ROU asset based on the remeasured lease liability, adjusted for any unamortized lease incentives received, any unamortized initial direct costs and the cumulative difference between rent expense and amounts paid under the

lease agreement. Any lease incentives received and any initial direct costs are amortized on a straight-line basis over the expected lease term. Rent expense is recorded on a straight-line basis over the expected lease term.

Research and Development Expenses

Research and development expenses consist of costs incurred in connection with the Company's discovery efforts, and the preclinical and formulation development of its product candidates. Research and development expenses are charged to operating expenses as incurred.

Patent Costs

Costs related to filing and pursuing patent applications are recorded as general and administrative expenses in the statements of operations and expensed as incurred since recoverability of such expenditures is uncertain.

Stock-Based Compensation

Stock options and restricted stock issued pursuant to the Company’s 2021 Equity Incentive Plan (the “2021 Plan”) and 2018 Equity Incentive Plan (the “2018 Plan”), and option features associated with the rights to purchase shares pursuant to the Company’s 2021 Employee Stock Purchase Plan (the “ESPP”) are valued using the Black-Scholes option pricing model on the date of grant or subscription period. This option pricing model involves a number of estimates, including the expected lives of the stock options or subscription period, the Company's anticipated stock volatility and interest rates. The Company recognizes the expense for equity awards on a straight-line basis over the requisite service periods of the awards or the number of shares estimated to be issued pursuant to the ESPP. Forfeitures are recognized as they occur.

Income Taxes

The Company uses the asset and liability method of accounting for income taxes. Under this method, deferred tax assets and liabilities are determined based on the difference between the financial reporting and the tax reporting basis of assets and liabilities and are measured using the enacted tax rates and laws that are expected to be in effect when the differences are expected to reverse. The Company provides a valuation allowance against net deferred tax assets unless, based upon the available evidence, it is more likely than not that the deferred tax assets will be realized. When the Company establishes or reduces the valuation allowance against its deferred tax assets, its provision for income taxes will increase or decrease, respectively, in the period such determination is made.

The accounting guidance for uncertainty in income taxes prescribes a recognition threshold and measurement attribute criteria for the financial statement recognition and measurement of tax positions taken or expected to be taken in a tax return. For those benefits to be recognized, a tax position must be more likely than not to be sustained upon examination by taxing authorities based on the technical merits of the position.

Stock-Based Compensation (Tables)

12 Months Ended

Dec. 31, 2021

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

Summary of Stock Option Activity

A summary of the Company's stock option activity for the periods presented was as follows (in thousands, except year, share and per share data):


						Weighted-
						Average
	Number of			Weighted-		Remaining
	Options and			Average		Contractual		Aggregate
	Awards			Exercise		Term		Intrinsic
	Outstanding			Price		(Years)		Value
Outstanding at December 31, 2019		30,674		$	0.003		9.95	$	—
Granted		1,723,913		$	0.93
Exercised		(153,373	)	$	0.95
Canceled		—		$	—
Outstanding at December 31, 2020		1,601,214		$	0.91		9.71		8,468
Granted		1,439,444		$	15.60
Exercised		(52,974	)	$	0.65
Canceled		(313,909	)	$	3.82
Outstanding at December 31, 2021		2,673,775		$	8.49		9.12	$	35,343
Vested and expected to vest at December 31, 2021		2,673,775		$	8.49		9.12	$	35,343
Exercisable at December 31, 2021		949,102		$	2.34		8.78	$	18,159

Weighted-Average Assumptions Used in Black-Scholes Option Pricing Model to Determine Fair Value of Stock Option Grants

The weighted-average assumptions used in the Black-Scholes option pricing model to determine the fair value of stock option grants for the periods presented were as follows:


	Year Ended December 31,
	2021			2020
Fair value of common stock		15.60			5.08
Expected term (years)		6.07			6.32
Expected volatility		72.83	%		72.93	%
Risk-free interest rate		1.04	%		0.62	%
Expected dividend yield		0.0	%		0.0	%

Stock-Based Compensation Expense for Equity Awards Reported in Statements of Operations and Comprehensive Loss

Stock-based compensation expense for all equity awards has been reported in the statements of operations and comprehensive loss as follows (in thousands):


	Year Ended December 31,
	2021		2020
Research and development	$	1,827	$	177
General and administrative		2,862		273
Total	$	4,689	$	450

2021 Employee Stock Purchase Plan

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

Weighted-Average Assumptions Used in Black-Scholes Option Pricing Model to Determine Fair Value of Stock Option Grants


	Year Ended December 31,
	2021
Fair value of common stock		19.96
Expected term (years)		1.41
Expected volatility		69.26	%
Risk-free interest rate		0.18	%
Expected dividend yield		0.0	%

Grant Revenue - Additional Information (Details) - USD ($)	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
Grant
Disaggregation Of Revenue [Line Items]
Recognized grant revenue	$ 0	$ 200,000

- Definition

Amount, including tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value-added and excise.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 41
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e9038-108599

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 5
-URI http://asc.fasb.org/extlink&oid=123351226&loc=SL49130545-203045

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 30
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 22
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 22
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 4
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=123351226&loc=SL49130543-203045

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 42
-URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e9054-108599

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 40
-URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e9031-108599

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 924
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SAB Topic 11.L)
-URI http://asc.fasb.org/extlink&oid=6472922&loc=d3e499488-122856

+ Details

Stock-Based Compensation - Additional Information (Details) - USD ($)		12 Months Ended
	Mar. 25, 2021	Dec. 31, 2021	Dec. 31, 2020	Jan. 01, 2022
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Weighted-average grant date fair value per share of options granted		$ 12.39	$ 4.49
Aggregate intrinsic value of options exercised		$ 800	$ 0
Cash received from options exercised		$ 34,000	$ 1,000
Expected dividend yield		0.00%	0.00%
Unrecognized compensation expense		$ 18,000,000.0
Weighted-average period in expense expected to be recognized		3 years 2 months 12 days
Maximum
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Cash received from options exercised		$ 100,000	$ 100,000
2021 Equity Incentive Award Plan
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Common stock reserved for issuance	6,118,648
Common stock remained available for issuance		6,079,984
Common stock issuance, description and terms		the number of shares of common stock available for issuance under the 2021 Plan will automatically increase on January 1 of each calendar year, starting on January 1, 2022 through January 1, 2031, in an amount equal to 5% of the total number of shares outstanding of the Company’s common stock on the last day of the calendar month before the date of each automatic increase, or a lesser number of shares determined by the Company’s board of directors.
2021 Equity Incentive Award Plan \| Subsequent Event
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Common stock reserved for issuance				8,864,071
Number of shares available for future issuance increased				2,784,087
2018 Equity Incentive Plan
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Common stock remained available for issuance	881,352
2021 Employee Stock Purchase Plan
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Common stock reserved for issuance	600,000	588,544
Common stock remained available for issuance	1,200,000
Common stock issuance, description and terms		the number of shares of common stock available for issuance under the ESPP will automatically increase on January 1 of each calendar year, starting on January 1, 2022 through January 1, 2031, in an amount equal to the lesser of (i) 1% of the total number of shares outstanding of the Company’s common stock on the last day of the calendar month before the date of each automatic increase and (ii) 1,200,000 shares; provided that before the date of any such increase, the Company’s board of directors may determine that such increase will be less than the amount set forth in clauses (i) and (ii).
Expected dividend yield		0.00%
Maximum percentage of eligible earnings withheld to participate in offering	15.00%
Price of common stock purchased	85.00%
Issuance of common stock under employee stock purchase plan, Shares		11,456
Unrecognized compensation expense		$ 400,000
Weighted-average period in expense expected to be recognized		1 year 9 months 18 days
2021 Employee Stock Purchase Plan \| Subsequent Event
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Common stock reserved for issuance				1,145,361
Number of shares available for future issuance increased				556,817

Income Taxes - Schedule of Reconciliation of Income Tax Expense (Benefit) (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
Income Tax Disclosure [Abstract]
Expected tax benefit at federal statutory rate	$ (7,451)	$ (1,738)
State income taxes, net of federal benefit	(4)	(552)
Debt financing		6
Research and development credits	(836)	(71)
Other	317	174
Change in valuation allowance	$ 7,974	$ 2,181

Income Taxes - Summary of Changes to Unrecognized Tax Benefits (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
Income Tax Disclosure [Abstract]
Balance at beginning of period	$ 15	$ 9
Increase related to prior year tax positions	1
Increase to current year tax positions	402	6
Balance at end of period	$ 418	$ 15

Statements of Convertible Preferred stock and Stockholders' Equity (Deficit) (Parenthetical) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
Series B Convertible Preferred Stock
Preferred stock issuance costs	$ 288
Series A Convertible Preferred Stock
Preferred stock issuance costs		$ 270
Initial Public Offering
Stock issuance costs	$ 21,728

Lease

12 Months Ended

Dec. 31, 2021

Leases [Abstract]

Lease

7. Lease

In May 2019 the Company entered into an agreement, as subsequently amended, to lease laboratory space pursuant to a three-month, automatically renewing lease. Due to the short-term nature of the lease, it was not included as an operating lease right of use asset nor as an operating lease liability on the Company’s balance sheets. The Company terminated the agreement in September 2021.

In February 2021, the Company entered into a lease agreement with Crossing Holdings, LLC to rent approximately 12,370 square feet of laboratory and office space (the “Lease”). The Company’s Executive Chairperson, co-founder and member of its board of directors, is the sole member and Manager of Crossing Holdings, LLC. The lease commenced in September 2021 with a term of 72 months and an option to extend the lease term for a period of three years; however, it is not reasonably certain the Company will exercise the option to renew when the lease term ends in 2027, and thus, the incremental term was excluded from the calculation of the ROU asset, related party and lease liability, related party. The lease includes variable non-lease components (e.g., common area maintenance, maintenance, etc.) that are not included in the ROU asset, related party and operating lease liability, related party and are reflected as an expense in the period incurred. Lease payments are subject to annual increases of 3% and the Company is responsible for its share of operating expenses and taxes, which are expensed as incurred. As of December 31, 2021, the remaining lease term for the lease was 5.7 years and the discount rate used to determine the right-of-use asset and corresponding operating lease liability was 7.15%.

Maturities of operating lease liabilities, related party as of December 31, 2021 are as follows (in thousands):


2022	$	733
2023		755
2024		778
2025		801
2026		825
Thereafter		561
Total future minimum lease payments		4,453
Less: Present value adjustment		(820	)
Operating lease liabilities, related party	$	3,633

Rent expense for the years ended December 31, 2021 and 2020 was $0.6 million and $0.1 million, respectively.